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ABSTRACT
Cancer is one of the leading cause of death in the world. Since tumorigenesis was 
described as a multistep mechanism in 1958 by Foulds, important progresses are 
obtained in the research field. Through these years many altered mechanisms 
were discovered revealing a very intricate picture of this disease. Mutations, 
epigenetic changes, aneuploidy imply severe modifications in nai've cellular 
pathways involved in every feature of cell life.
p38 MAPK is a family of kinases composed by four isoforms: alpha, beta, delta 
and gamma. These kinases are involved in several important cellular pathways, 
from the differentiation of muscle cells to inflammation and also in cancer 
progression. The pharmacologic and genetic inhibition of p38 alpha in colorectal 
cancer cells induced cell cycle arrest, autophagy and then cell death with 
autophagic features.
My PhD project is focused on the understanding the role of p38 alpha in the 
autophagic activation in colorectal cancer cell lines, finding that its inhibition 
induced the decrease of HIF-1 alpha protein levels and its glycolytic 
transcriptional program. Moreover, p38 alpha inhibition trigger the activation of 
Fox03A-dependent transcription, which is related to cell cycle arrest, autopahgy 
and cell death. We checked for other HIF-1 alpha-dependent tumors which 
shown also overactivation of p38 alpha, such as ovarian cancer and prostate 
cancer. In these kind of tumors we obtained the same encouraging results.
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However, in the DU 145 prostate cancer cell line, the inhibition of p38 alpha 
failed to activate autophagic pathway due to the lack of LKB1 kinase, which is 
the upstream activator of AMPK. In this cell line the inhibition of p38 alpha 
triggered apoptotic pathway. Chemoresistance is one of the main obstacle in the 
treatment of cancer. A part of my PhD project is based on the study of p38 alpha 
role in cisplatin chemoresistance in colorectal cancer cells. Surprisingly, we 
found that its inhibition, together with the administration of cisplatin, induced 
apoptotic cell death in the resistant HT29 cell line and increased the effect of cell 
death in the responsive HCT116 cell line, through the activation of Fox03A. All 
these evidences indicated that inhibition of p38 alpha could be used as a 
promising therapeutic approaches for colorectal cancer and other malignancy, 
through the activation of Fox03A-dependent transcription program.
R
Chapter 1: INTRODUCTION
1.1 Aspect of cancer
Cancer is a major public health problem in the United States and many other 
parts of the world. One in 4 deaths in the United States is due to cancer (Siegel et 
al., 2012). Over the past 30 years, significant progress has been achieved in 
understanding the molecular basis of cancer. The accumulation of this basic 
knowledge has established that cancer is a variety of distinct diseases caused by 
different defective genes. Further, gene defects are diverse in nature and can 
involve either loss or gain of gene functions.
While cancer is clearly associated with an increase in cell number, alterations in 
mechanisms regulating new cell birth, or cell proliferation, are only one facet of 
the mechanisms of cancer. Decreased rates of cell death, i.e. apoptosis, are now 
known to contribute to certain types of cancer. At least five rate-limiting steps 
must be overcome before a clinically observable tumor could arise. These rate- 
limiting steps are genetic mutations that deregulate the activities of genes that 
control cell growth, regulate sensitivity to programmed cell death, and maintain 
genetic stability. Hence, tumorigenesis is a multistep process. Although the 
processes that occur during tumorigenesis are only incompletely understood, it is 
clear that the successive accumulation of mutations in key genes is the force that 
drives tumorigenesis. Each successive mutation is thought to provide the 
developing tumor cell with important growth advantages that allow cell clones to 
outgrow their normal neighboring cells. Importantly, it was found that no single
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oncogene could confer all of the physiological traits of a transformed cell to a 
normal cell. Rather this required that at least two oncogenes acting cooperatively 
to give rise to cells with the fully transformed phenotype (Land et al., 1983). 
Carcinogenesis is the process that leads to genetic mutations induced by physical 
or chemical agents. Conceptually, this process can be divided into three distinct 
stages: initiation, promotion, and progression (Hennings et al., 1993). Initiation 
involves an irreversible genetic change, usually a mutation in a single gene. 
Promotion is generally associated with increased proliferation of initiated cells, 
leading to increase of this population. Progression is the accumulation of more 
genetic mutations which lead to the acquisition of the malignant or invasive 
phenotype. The initiation step, probably, is the most important step because it is 
an irreversible event that occurs when different causes produce DNA mutations. 
The different types of mutations that can occur include point mutations, deletions, 
insertions, chromosomal translocations, and amplifications. Three important steps 
involved in initiation are carcinogen metabolism, DNA repair, and cell 
proliferation. Hence, DNA repair is essential to reverse and to prevent DNA 
damage. Failure in the repair mechanisms, followed by cell proliferation, results 
in permanent alterations or mutation(s) in the genome that can lead to oncogene 
activation or inactivation of tumor suppressor genes.
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1.1.1 Oncogenes and tumor suppressor
Oncogenes are derived from normal host genes, also called proto-oncogenes, that 
become deregulated as a consequence of mutation. Oncogenes contribute to the 
transformation process by driving cell proliferation or reducing sensitivity to cell 
death. Historically, oncogenes were identified in four major ways: chromosomal 
translocation, gene amplification, RNA tumor viruses, and gene transfer 
experiments. There are seven classes of oncogenes, classified by their location in 
the cell and their biochemical activity. All of these oncogenes have different 
properties that can lead to cancer. The classes of oncogenes are growth factors, 
growth factor receptors, membrane-associated guanine nucleotide-binding 
proteins, serine-threonine protein kinases, cytoplasmic tyrosine kinases, nuclear 
proteins, and cytoplasmic proteins that affect cell survival. Among these classes 
of oncogenes, of particular importance is the role of nuclear protein, which are 
also called transcription factors.
One of the transcription factor involved in tumorigenesis is CMYC (Henriksson 
and Luscher, 1996). Deregulation of CMYC often occurs either by gene 
rearrangement (Zhao et al., 2008b) or amplification in human cancers (Deming et 
al., 2000). The overproduction of CMYC results in uncontrolled cell 
proliferation. CMYC overexpression occurs both in solid and hematologic tumors 
such as Burkitfs lymphoma (Mitchell et al., 1984), and is usually the result of 
gene amplification (Koskinen and Alitalo, 1993). The oncogenic potential of 
CMYC has been studied most widely as it pertains to the development of colon
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cancer (Rochlitz et al., 1996). Both CMYC RNA and protein are overexpressed at 
the early and late stages of colorectal tumorigenesis (Rochlitz et al., 1996).
Cell growth and proliferation are subject to regulation by external signals that are 
typically transmitted to the cell by growth factors (i.e. EGF (Cohen, 1983)) that 
bind to and activate specific receptors (i.e, EGFR (Yarden and Schlessinger, 
1987)); In many cases, signaling that is initiated by growth factors activating 
their receptors passes next to membrane associated guanine nucleotide-binding 
proteins, which when activated by mutation, constitute another class of 
oncogenes (i.e. HRAS, KRAS and NRAS). Once activated, RAS then transmits the 
growth signal to a third class of signaling molecules that is comprised of the 
serine/thereonine kinases. The best studied of these serine-threonine protein 
kinases is the RAF oncogene (Stokoe et al., 1994). RAF then initiates a cascade 
of mitogen-induced protein kinases (MAPKs), Another RAS effector gene is 
phosphoinositol 3-kinase (PI3K), which initiates a signaling pathway for cell 
survival (Rodriguez-Viciana et al., 1994). This signalling pathway in cancer leads 
to the transduction of different stimuli to the nucleus, where transcription factor 
are able to transcribe all those genes usefull for proliferation, avoiding all systems 
for the control of cell growth.
In contrast to oncogenes, tumor suppressor genes can directly or indirectly inhibit 
cell growth. Those that directly inhibit cell growth or promote cell death are 
known as “gatekeepers”. Both copies of gatekeeper tumor suppressors must be 
functionally eliminated for tumor development. Mutations that inactivate one 
allele of a gatekeeper gene can be inherited through the germline, leading to
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cancer predisposition syndromes. Those tumor suppressor genes that do not 
directly suppress proliferation, but promote genetic stability are known as 
caretakers. Caretakers regulate DNA repair pathways and their inactivation 
results in increased mutation rates. Because numerous mutations are required for 
the full development of a tumor, elimination of caretaker tumor suppressors can 
greatly accelerate tumor progression. The most studied tumor suppressors are 
retinoblatoma protein (RB), p53, adenomatous polyposis coli (APC) and 
Phosphatase and tensin homolog-10 (PTEN) .
RB is related to retinoblastoma syndrome and is childhood disease. RB was the 
first human tumor suppressor gene identified, and the loss of RB protein function 
leads to malignancy and is dysfunctional in several major cancers (Murphree and 
Benedict, 1984). The RB protein is localized in the nucleus where it is either 
phosphorylated or unphosphorylated . When unphosphorylated, RB binds to the 
E2F transcription factor and prevents transcriptional activation of E2F target 
genes. When phosphorylated, RB can no longer bind to E2F. When loss of RB 
function occurs because of various mutations in the RB, the cell cycle becomes 
deregulated, and uncontrolled cell division results (De et al., 2006).
The tumor suppressor APC is mutated in almost 90% of human colorectal 
cancers (CRC) (Markowitz and Bertagnolli, 2009) and 30% of melanoma skin 
cancers (Worm et al., 2004). The inherited loss of APC tumor suppressor 
function results in familial adenomatous polyposis (FAP). Deletion of APC 
alleles, or mutations causing truncations in APC that influence its interaction with 
beta-catenin (CTNNB1), leading to its stabilization and activation of
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Tcf/lymphoid enhancing factor (Lef)-dependent gene expression. One of the 
genes transcribed by this complex is the oncogene CMYC. However, APC could 
be wild type in CRC. Mutations in CTNNB1 that abrogate its regulation by APC 
represent an alternative route to WNT activation and do occur more commonly in 
sporadic cancers outside of the gut. These mutations were first identified in 
sporadic CRC (Korinek et al., 1997; Morin et al., 1997) and in melanoma 
(Rubinfeld et al., 1997), but subsequent sequencing efforts indicated that they 
occur quite infrequently in these cancers (Demunter et al., 2002; Johnson et al., 
2005; Luchtenborg et al., 2005; Thorstensen et al., 2005).
PTEN was first tumor suppressor gene identified in the most aggressive form of 
brain cancer, glioblastoma multiform (Simpson and Parsons, 2001). PTEN also is 
mutated in a significant fraction of endometrial carcinomas, prostate carcinomas , 
and melanomas (Tashiro et al., 1997; Gray et al., 1995; Celebi et al., 2000). Its 
tumor suppressor role is correlated with the induction of cell cycle arrest and 
apoptosis (Chu and Tamawski, 2004). PTEN is a dual-specificity phosphatase, 
meaning that it can dephosphorylate proteins on serine, threonine, and tyrosine 
residues. It antagonizes the function of PI3K. PTEN, therefore, acts as a negative 
regulator of AKT activation (Maehama and Dixon, 1999), inducing apoptosis of 
mutated or stressed cells to prevent tumor formation. PTEN suppresses the PI3 Re­
mediated induction of blood vessel growth factors like VEGF (Tian et al., 2010; 
Ma et al., 2009). PTEN also inhibits cell migration and formation of focal 
adhesions when overexpressed in glioblastoma cell lines, suggesting that it helps 
to inhibit metastasis as well (Tamura et al., 1998). The best known and studied
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tumor suppressor is p53. This protein is activated in response to a wide variety of 
cellular stresses including DNA damage, ribonucleotide depletion, redox 
modulation, hypoxia, changes in cell adhesion, and the stresses created by 
activated oncogenes. The p53 protein functions as a transcription factor that, 
when activated, stimulates the expression of a variety of effectors that bring about 
growth arrest, promote DNA repair, and stimulate cell death by apoptosis. 
Collectively these activities act to maintain genomic stability. Elimination of p53 
function leads to increased rates of mutation and resistance to apoptosis. 
Consequently, mutations in p53 are the most frequent genetic change encountered 
in human cancers.
Since the main effect of tumor progression is uncontrolled proliferation, it is clear 
how one of the way to stop tumor formation is to block the cell division. 
However, the capacity of these cells to overcame cell cycle check points leads to 
find different strategies for the elimination of aberrant cells. The main way for 
this targeted elimination is the activation of cell death. Different types of cell 
deaths have been described (Galluzzi et al., 2012) but the most studied and 
characterized are Apoptosis and Autophagy.
Apoptosis is a tightly regulated multi-step pathway that is responsible for cell 
death not only during development, but also in adult multicellular organisms, in 
which it partly controls cell numbers. It is characterized by cell shrinkage, 
chromatin condensation, nuclear and cell fragmentation. These features result in 
the formation of apoptotic bodies that are then engulfed by neighbouring 
phagocytic cells. Autophagy is a very well regulated intracellular pathway and is
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a process evolutionary conserved, from yeast to human. Its role consist of 
breaking macromolecules, membranes and entire organelles to obtain essential 
components. Autophagic degradation is used for three ends: elimination of old 
and not functional organelles, turnover of short-lived proteins and recovery of 
energetic balance due to particular environmental conditions, such as starvation. 
In addition, defects in autophagy have been linked to a wide range of diseases in 
mammalian cells indicating that autophagy is crucial in physiology (Liang et al., 
1999).
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1.2 COLORECTAL CANCER
1.2.1 Introduction to the pathology
Colorectal cancer (CRC) is a major health concern, with more than 1 000 000 
new cases and 500 000 deaths expected worldwide per year (Samoha and Arber, 
2005). Prognostic evaluation is currently based on histological appearance, and 
there are no molecular markers internationally recognized as standard predictor 
factors. The conventional therapy involving surgery and adjuvant therapy seems 
to give rise to improvements in progression-free and overall survival. 
Nevertheless about 50% of patients die within 5 years owing to metastasis or 
recurrent disease (McGartland et al., 2004). The prospects for further substantial 
advances in the management of CRC reside in a systematic genetic and 
functional dissection of cell cycle and cell death regulatory pathways in tumor 
cells in order to identify differential cellular effects of agents that may have a 
direct impact on cancer therapy. Tumorigenesis has long been thought to be a 
multistep process, since 1958 Foulds proposed is model (FOULDS, 1958). 
Fearon and Vogelstein were the first authors to propose a multistep model for 
CRC, in which were explained the genetic causes of progression from adenomas 
to cancer (Fearon and Vogelstein, 1990). For the authors this model is composed 
by four salient features: first, colorectal tumors appear to arise as a result of the 
mutational activation of tumor suppressor genes, the latter changes predominate; 
second, mutations in at least four to five genes are required for the formation of a
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malignant tumor, fewer changes suffice for benign tumorigenesis; third, although 
the genetic alterations often occur according to a preferred sequence, the total 
accumulation of changes, rather than their order with respect to one another, is 
responsible for detemining the tumor’s biologic properties; fourth, in some cases, 
mutant tumor suppressor genes may not be "recessive" at the cellular level 
(Fearon and Vogelstein, 1990).
Hence, according to the model developed by Vogelstein and coworkers, 
colorectal neoplasia evolves through a series of genetic alterations that includes 
the activation of oncogenes by mutations and the inactivation of tumor suppressor 
genes by mutation, loss, or methylation (Vogelstein et al., 1988) (Figure 1). 
These alterations occur in steps such that successive suBCLones gain a survival 
or growth advantage over their neighbors until a final suBCLone emerges with 
the potential for invasion and metastasis. The malignant suBCLone will grow and 
eventually efface all trace of the precursor lesion, but will nevertheless contain 
within its genome a permanent record of the underlying genetic changes. A 
surprising feature of this model is the relative rapidity of an evolutionary 
sequence that requires the accumulation of a multitude of genetic changes within 
a single cell. Key insights in explaining multistep oncogenesis were derived from 
the lessons of CRC (Kinzler and Vogelstein, 1996). FAP indicated how biallelic 
silencing of the tumor suppressor APC could initiate adenomas while Lynch 
syndrome or hereditary nonpolyposis colorectal cancer (HNPCC) highlighted the 
feature of genetic instability as the explanation for rapid neoplastic progression. 
Genetic instability not only accounts for loss of fidelity with respect to genomic
1R
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Figure 1. Genetic mutation in CRC progression. At least 4 mutations are necessary for 
the trasformation in cancer of normal epithelium (Vogelstein et al., 1988). In this model 
APC mutation is the leading mutation for cancer initiation.
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replication during cell division, but also implicates the breakdown of cellular 
mechanisms that would normally detect DNA damage and trigger apoptosis.
1.2.2 The Wnt pathway in CRC
A large body of recent studies points the WNT signaling pathway as the unique 
player in the physiology of the intestine Figure 2. Several secreted WNT factors 
are secreted by the epithelial cells at the crypt bottom (Gregorieff et al., 2005), 
with the creation of a morphogen-like gradient of WNT signals along the crypt- 
villus axis (Logan and Nusse, 2004). Genetic studies in Drosophila and 
Caenorhabditis elegans, ectopic gene expression in Xenopus, and gene knockout 
mice have demonstrated the contribution of WNTs in very different processes 
such as segmentation, CNS patterning, and control of asymmetric cell divisions. 
The identification of Frizzled proteins as cell surface receptors for WNTs and the 
finding that CTNNB1, a downstream effector of the surface receptor, can 
translocate to the nucleus and function as a transcriptional activator led to a better 
understanding of WNT signaling (Wodarz and Nusse, 1998). WNT genes, of 
which the human and the mouse genome harbor almost 20 members, encode for 
cysteine-rich glycoproteins. Once secreted into intracellular environment from 
mesenchimal and intestinal pericryptal fibroblasts (Bienz and Clevers, 2000), 
WNT interact with other secreted proteins such as Frizzled-related proteins 
(SFRPs) and WNT inhibitory factor (WIF). Signaling is prompted when WNT 
ligands bind their cognate receptor complex, including the serpentine receptor of
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Frizzled proteins and the single-span transmembrane protein Lrp5/6 of the LDL 
receptor family (Bhanot et al., 1996; Pinson et al., 2000; Tamai et al., 2000; 
Wehrli et al., 2000). WNTs may simultaneously bind to Frizzled and LRP 
receptor, laying the first step of the so-called canonical pathway, with the 
formation of nuclear TCF/CTNNB1 complex. The cytoplasmatic protein 
CTNNB1, the stability of which is regulated by the destruction complex, is the 
key player of the WNT canonical cascade. When WNT receptors are not 
engaged, two scaffolding proteins in the destruction complex, the tumor 
suppressor APC and AXIN/AXIN2 sequester newly synthesized CTNNB1 
allowing casein kinase I (CKI) to phosphorylate the N-terminus of CTNNB1 at 
Ser S45, a residue often mutated in CRC (Amit et al., 2002). Then, glycogen 
synthase kinase 3 beta (GSK3beta) phosphorylate additional serine and threonine 
residues N-terminal to S45 (Rubinfeld et al., 1996). The resulting phosphorylated 
footprint of CTNNB1 recruits a beta-TrCP-containing E3 ubiquitin ligase, which 
mediates ubiquitination of CTNNB1 and its proteasomal degradation (Hart et al., 
1999; Kitagawa et al., 1999; Winston et al., 1999). Under physiological 
conditions, continued destruction of CTNNB1 is interrupted by receptor 
occupancy that inhibits the kinase activity by an incompletely understood 
mechanism involving the direct interaction of AXIN and Lrp5/6 or the actions of 
axin-binding adapter protein, Dishevelled, in association with Frizzled and 
GSK3beta-binding protein, Frat (Yost et al., 1998; Chen et al., 2003; Wong et al.,
2003). Another mechanism proposed that WNTs induce phosphorylation of the 
cytoplasmatic tail of Lrp5/6, which allows the docking of AXIN (Tamai et al.,
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2004). Thus, the recruitment of AXIN to the membrane is thought to avoid the 
formation of the destruction complex, with the subsequent release of the 
CTNNB1. Stabilized CTNNB1 is somehow released from the AXIN complex 
and translocates to the nucleus. Once in the nucleus, it associates with members 
of the TCF family of transcription factors (TCF1, LEF, TCF3, and TCF4) 
(Waterman, 2004) (Figure 2). Actually, TCFs target CTNNB1 to specific DNA 
elements present in promoters and enhancers of known target genes (Behrens et 
al., 1996; Molenaar et al., 1996), and in turn CTNNB1 serves as a coactivator of 
TCFs to stimulate transcription of WNT target genes recruiting a number of 
nuclear factors responsible for transactivating TCF target genes. Among these 
nuclear factors, two key members are the histone acetylase CBP/p300 and the 
SWI/SNF component BRG1 (Hecht et al., 2000; Takemaru and Moon, 2000; 
Barker et al., 2001; Simone, 2006). Activation o f TCF target genes is dependent 
also by other nuclear proteins, Legless and Pygopus, that are proposed to be 
directly involved in the activation of transcription recruiting chromatin 
remodeling factors, and in the transport of CTNNB1 to the nucleus (Kramps et 
al., 2002; Parker et al., 2002; Townsley et al., 2004). Accumulation of 
CTNNB1/TCF complex imposes a proliferative phenotype by inducing the 
expression of cell cycle promoting proteins such as CyclinDl (Shtutman et al., 
1999) and CMYC (He et al., 1998). Mutational inactivation of APC leads to 
inappropriate high levels of free CTNNB1, whose stabilization is thought to be 
critical in tumorigenesis (Korinek et al., 1997). Indeed, it is well known that the 
tumor suppressor role of APC is mediated by its ability to destabilize free
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Figure 2. The canonical WNT signalling pathway. In the absence of WNT 
signalling (left panel), CTNNB1 is in a complex with axin, APC and GSK3-beta, 
and gets phosphorylated and targeted for degradation. CTNNB1 also exists in a 
cadherin bound form and regulates cell-cell adhesion. In the presence of WNT 
signalling (right panel), CTNNB1 is uncoupled from the degradation complex 
and translocates to the nucleus, where its binds Lef/Tcf transcription factors, thus 
activating target genes (Reya and Clevers, 2005).
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CTNNB1 (Smits et al., 1999). Truncation of APC removes repetitive elements 
that allow APC to dock CTNNB1 and AXIN, with consequent impairment of 
GSK3beta mediated phosphorylation and degradation (Nathke, 2004). The 
evidence that CTNNB1 can be the first player in the initiation of malignant 
development was supported by the discoveries of other mutations in WNT 
signaling genes which cause free CTNNB1 accumulation. Moreover, in 15% of 
colon carcinomas that have conserved wild type APC, there are point mutations 
in one of the four serine/threonine residues located at the N-terminus of CTNNB1 
that are the known targets of CKl/GSK3beta (Morin et al., 1997; Ilyas et al., 
1997). Consequently, mutant CTNNB1 is no longer recognized by beta-TrCP and 
does not undergo proteosomal degradation.
1.2.3 Genetic CRC syndromes
CRC has one of the largest proportions of familial cases. Kindred and twin 
studies estimated that approximately 30% of all CRC cases are an inherited form 
of the disease (Lichtenstein et al., 2000; Grady, 2003). The syndromes involving 
CRC are defined on the basis of clinical, pathological, and more recently, genetic 
findings. Conditions that express adenomatous polyps include HNPCC, FAP, 
attenuated FAP, and MUTYH-associated polyposis (MAP). Hamartomatous 
polyps are the primary lesions in Peutz-Jeghers syndrome (PJS) and juvenile 
polyposis syndrome (JPS). Finally, hyperplastic polyposis (HPP) is an unusual 
condition that has a substantial cancer risk and must be distinguished from the
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other conditions. All of these conditions are inherited, autosomal dominant 
disorders, except MAP, which is an autosomal recessive, and HPP, which is 
rarely inherited.
1.2.3.1 Hereditary Non Polyposis Colorectal Cancer
Originally described in the early 20th century, elaborated on by Henry Lynch 
(Lynch, 1974), and refined through consensus conferences (Vasen et al., 1991; 
Vasen et al., 1999), this syndrome is marked by an autosomal dominant mode of 
inheritance, early onset of CRC often with a predilection for the right colon, and 
an 80% lifetime risk of CRC. The syndrome is noteworthy for a spectrum of 
extracolonic tumors, such as those originating from the endometrium, ovary, 
stomach, bile duct, kidney, bladder, ureter, and skin.
The syndrome accounts for 2%-4% of all CRCs (Hampel et al., 2008). Although 
affected individuals can develop colonic adenomas with greater frequency than 
the general population, polyposis is rare. The lifetime CRC risk is estimated to be 
50%- 80% (Stoffel et al., 2009). CRCs and polyps arise in HNPCC at a younger 
age of onset and a more proximal location compared to sporadic neoplams. 
Histologically, cancers are often poorly differentiated, mucinous, and -have large 
numbers of tumor-infiltrating lymphocytes. Lynch syndrome is the result o f a 
germline mutation in a class of genes involved in DNA mismatch repair (MMR), 
including hMSH2, hMLHl, hMSH6, and hPMS2. The MMR system is necessary 
for maintaining genomic stability by correcting single-base mismatches and
22
insertion-deletion loops that form during DNA replication. As a result, DNA 
replication errors occur in repeat sequences (Aaltonen et al., 1993); (Fishel et al., 
1993; Ionov et al., 1993), typically in dinucleotide repeats, and are designated as 
the mutator phenotype. This phenotype can be revealed by PCR-based 
interrogation of genome-wide microsatellite sequences to evaluate for the 
possibility of length changes in the microsatellite sequences called microsatellite 
instability (MSI). The tumor is referred to as MSI-high or MSI-H when two or 
more markers of the recommended panel by the National Cancer Institute 
(BAT26, BAT25, D5S346, D2S123, and D17S250 markers) demonstrate MSI, 
MSI-low or MSI-L with one unstable marker, or MSstable or MSS when no 
microsatellite loci are unstable. Of note, MSI may be found in ~15% of sporadic 
colorectal tumors (Thibodeau et al., 1998). Target genes of MSI include 
TGFbetallR, E2F4, and BAX, among others. Of interest is that CRCs with MSI-H 
overall have a better prognosis compared to those without MSI (Ribic et al.,
2003).
Mutations in hMSH2 and hMLHl account for the up to 90% of Lynch syndrome 
cases; mutations in hMSH6 account for approximately 10% and mutations in 
hPMS2 are detected on rare occasions (Rustgi, 2007; Peltomaki and Vasen,
2004). Differences in cancer risks have been reported among the MMR genes, 
including MSH6 where CRC risk may be slightly lower and endometrial cancer 
risk possibly higher compared to hMSH2 and hMLHl carriers (Plaschke et al.,
2004). The most striking difference is for hPMS2 mutation carriers which have 
recently been shown to have a 15%-20% risk for CRC, 15% for endometrial
23
cancer, and 25%-32% for any Lynch syndrome-associated cancer to age 70 years 
(Senter et al., 2008).
1.2.3.2 Familial Adenomatous Polyposis
FAP is the second-most common inherited. Features of FAP include the 
development of hundreds to thousands of colonic adenomas, beginning in early 
adolescence, and inevitable CRC in untreated individuals. The average age of 
CRC diagnosis if untreated is 39 years; 7% develop CRC by age 21 and 95% by 
age 50. Attenuated FAP is a less-severe form of the disease, characterized by an 
average 69% lifetime risk of CRC, an average of approximately 30 colonic 
adenomatous polyps (range 0 to 100s), the tendency to develop proximal colonic 
neoplasms, and a later age of polyp and CRC development (Burt et al., 2004). 
Nevertheless, the inevitable course is the development of CRC unless this 
distinctive natural history is interrupted by surgical intervention, typically in the 
form of total proctocolectomy with ileoanal anastomosis. Certain situations may 
mandate a subtotal colectomy with ileorectal anastomosis, but the rectal stump or 
remnant must be monitored for polyp recurrence. Extraintestinal manifestations 
include gastric fundic polyps, small bowel (especially duodenal) adenomatous 
polyps, congenital hypertrophy of the retinal pigment epithelium (CHRPE), 
supernumerary teeth, osteomas, cutaneous lipomas and cysts, thyroid tumors, 
desmoid tumors, adrenal cortical adenomas, and hepatoblastomas. While many of 
these features are benign, FAP patients may develop thyroid cancer, gastric
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adenocarcinoma (<1% lifetime risk), duodenal adenocarcinoma (5%-10% 
lifetime risk), and/or ampullary adenocarcinoma. Desmoid tumors, which are 
benign fibroblastic neoplasms (typically intra-abdominal), present a particularly 
vexing problem due to their proclivity to occur after colectomy and/or to recur 
after surgical removal of the desmoid tumor itself. Cytogenetic analysis 
associated FAP with an interstitial deletion on human chromosome 5q21 (Herrera 
et al., 1986), which was further expanded on by independent genetic linkage 
analyses to 5q21. Positional cloning verified the gene responsible for FAP to be 
the APC gene, a landmark effort (Groden et al., 1991; Kinzler et al., 1991; 
Nishisho et al., 1991).
The presence of extra-colonic lesions can also contribute to the initial diagnosis. 
FAP, attenuated FAP, and Gardner syndrome (FAP with epidermoid cysts, 
osteomas, dental anomalies, and/or desmoid tumors) all result from germline 
mutations in APC. The identification of APC mutations in a proband confirms the 
diagnosis, allowing precise identification of other relatives who are at risk. 
Attenuated FAP is suspected when 10 or more, but fewer than 100 adenomas, are 
found in a person over 40 or 50 years of age (Burt et al., 2004; Knudsen et al., 
2003). A precise diagnosis is often difficult in a single patient; polyp numbers 
vary with this disorder; attenuated FAP can mimic typical FAP, MAP, or even 
sporadic polyp development. Examinations of multiple family members can often 
determine the phenotype. Genetic testing is useful in that specific APC mutations 
are associated with attenuated FAP. Attenuated FAP and MAP, respectively, 
account for 10% to 20% of persons with 10 to 100 adenomatous polyps who do
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not have early classic FAP. It is common not to find a genetic etiology in this 
group. New or de novo APC mutations are responsible for approximately 25% of 
FAP cases. In addition, approximately 20% of individuals with an apparent de 
novo APC mutation have somatic mosaicism (Hes et al., 2008). The location of 
the mutation within APC  has been associated with the severity of colonic 
polyposis, the degree of cancer risk, and the presence and/or frequency of non- 
malignant findings, including desmoids and CHRPE (genotype-phenotype 
correlations) (Nieuwenhuis and Vasen, 2007). Studies have failed to show a 
correlation between genotype and upper GI tumor development.
1.2.3.3 Peutz-Jeghers Syndrome
PJS is a hamartomatous polyposis syndrome with an autosomal dominant mode 
of inheritance. The incidence is about one in every 200,000 births, and onset is in 
early childhood. Clinically, patients have moderate-large sized, but few 
hamartomatous polyps, typically in the small bowel but also in the colon and/or 
in the stomach. These polyps may enlarge and result in hemorrhage or 
intussusception with obstruction. However, the pathogonomic features are 
revealed through histopathology with increased smooth muscle bands. There is 
increased risk for CRC and, rarely, small bowel cancer (Giardiello et al., 2001). 
Other phenotypic features include macules with broad but focal distribution: 
peroral, buccal, periocular, palmar/plantar surfaces, and anogenital surfaces. 
Earlier genetic linkage studies localized the gene locus responsible for PJS to
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human chromosome 19pl3.3 (Amos et al., 1997). The actual gene was 
discovered to be a novel serine-threonine kinase 11 (STK11), or LKB-1 
(Hemminki et al., 1998; Resta et al., 1998). The tumors associated with PJS have 
19p LOH or somatic mutations in LKB1. Patients suspected to have PJS are 
candidates for genetic testing with evaluation for germline LKB1 mutations. 
Those identified patients, or patients at risk, should undergo periodic upper 
endoscopy, colonoscopy, and small bowel follow-through X-ray series; and 
meticulous attention to the risk of various cancers (especially pancreatic cancer).
1.2.3.4 Juvenile Polyposis Syndrome
JPS is an autosomal dominant disorder in which 10 or more juvenile polyps are 
observed in the GI tract. It affects one in 100,000 births, and the phenotypic 
manifestations are found in childhood to adolescence. The polyps, as with the 
polyps in PJS, may bleed or obstruct. The establishment of these hamartomatous 
polyps as juvenile polyps is predicated on histological interpretation and 
confirmation of microcysts in the epithelia. They are found in the colon, but also 
other parts of the GI tract. Germline mutations in BMPR1A (bone morphogenic 
protein receptor 1 A), SMAD4, or ENG (endoglin, an accessory receptor for TGF- 
beta) are reported in FJP (Howe et al., 1998; Howe et al., 2001; Sweet et al.,
2005), suggesting that the TGF-beta pathway is critical in the pathogenesis of 
FJP. Certain features seen in JPS, such gastric polyposis and HHT, are more 
common with SMAD4 mutations than with BMPR1A and might guide genetic
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testing strategies. Individuals with a clinical diagnosis of JPS but without an 
identifiable mutation in SMAD4 or BMPR1A could have another hamartomatous 
polyposis condition or an unidentified mutation.
1.2.3.R Actual therapy and drug resistance
Adjuvant chemotherapy improves overall and disease-free survival of patients 
with resected Dukes' stage C CRC. 5-Fluorouracil (5-FU)-based 
chemotherapeutic regimens are the standard treatment for these patients. 
However, response rates for 5-FU as a single first-line treatment in advanced 
CRC are only 10-15% (Johnston and Kaye, 2001). Combining 5-FU with the 
newer chemotherapies irinotecan (CPT-11) and oxaliplatin has improved 
response rates for advanced CRC to 40-50% (Giacchetti et al., 2000; Douillard et 
al., 2000). Despite these improvements, new therapeutic strategies are needed. 
The use of novel biological agents, such as the monoclonal antibodies, cetuximab 
(an EGFR inhibitor) and bevacizumab (BV) (a VEGF inhibitor), have recently 
been shown to provide additional clinical benefit for patients with metastatic 
CRC (Cunningham et al., 2004; Hurwitz et al., 2004). Cetuximab (Erbitux, 
Merck Serono) is a recombinant monoclonal antibody that blocks the human 
epidermal growth factor receptor (EGFR) and therefore inhibits the proliferation 
of cells that depend on EGFR activation for growth. Cetuximab is indicated for 
the treatment of patients with EGFR-expressing, Kirsten rat sarcoma (KRAS) 
wild-type metastatic CRC in combination with chemotherapy or as a single agent
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in patients who have failed oxaliplatin- and irinotecan-based therapy and who are 
intolerant to irinotecan.
The addition of BV to irinotecan, bolus 5-FU, and leucovorin combination (IFL) 
was associated with a high response rate (RR) as well as a significant longer time 
to progression (TTP) and overall survival (OS) in CRC patients (Hurwitz et al., 
2004). In a second-line setting, BV has also shown improved RR, progression- 
free survival (PFS), and OS, when combined with FOLFOX (oxaliplatin, 5-FU, 
and leucovorin). However, patients in the BV-only arm showed PFS rates lower 
than patients in the control (FOLFOX alone) arm (2.7 vs. 4.7 months) (Giantonio 
et al., 2007). Moreover, these agents are now under intense investigation in the 
adjuvant setting.
Resistance to chemotherapy limits the effectiveness of current cancer therapies, 
including those used to treat CRC. Drug resistance can be intrinsic or acquired 
during treatment and is believed to cause treatment failure in over 90% of 
patients with metastatic cancer. Furthermore, drug resistant micrometastic tumor 
cells are also likely to reduce the effectiveness of adjuvant chemotherapy 
following surgery. Overcoming drug resistance is one of the main challenges of 
current cancer research. Many factors affect drug sensitivity, such as the 
pharmacokinetic profile of the drug; drug activation and inactivation; alterations 
in the drug target; processing of drug- induced damage; and evasion of apoptosis. 
another problematic related to the chemotherapy is the presence of mutations in 
pathways targeted by chemotherapies; for example, cetuximab is effective only 
for those tumors wild type for KRAS, but this protein is usually mutated in CRC.
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1.3 OVARIAN CANCER
1.3.1 The "silent” killer
In 2002, there were an estimated 204,000 new cases of Ovarian Cancer (OvCa) 
and 125,000 deaths due to this disease worldwide (Parkin et al., 2005). The 
incidence rates of OvCa are highest in the Western world, where it is the leading 
cause of death from gynecological malignancies (Parkin et al., 2005; Jemal et al., 
2008). The 5 year survival rate of OvCa ranges from 30 to 92%, depending on the 
spread of disease at diagnosis (Jemal et al., 2008). OvCa is associated with high 
morbidity and mortality because approximately 75% of patients present with 
evidence of metastatic spread beyond the ovaries (FIGO stages (the International 
Federation of Gynecology and Obstetrics stages) III and IV) and require 
combined surgery and chemotherapy (Dinh et al., 2008).
The evolution of surgical techniques and chemotherapy regimens through 
multiple clinical trials over the past three decades has resulted in improvements 
in OvCa treatment (Agarwal and Kaye, 2003; Balvert-Locht et al., 1991). 
Debulking surgery remains key in OvCa treatment; a residual tumor size of 
greater than 2 cm is associated with a reduced survival of 12-16 months, 
compared with 40-45 months if the tumor is less than 2 cm (Mutch, 2002).
OvCa has a distinctive biology and behavior at the clinical, cellular and 
molecular levels. Clinically, OvCa is often present as a complex cystic mass in 
the pelvis. Although OvCa has been termed the 'silent killer’, more than 80% of
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patients have symptoms, even when the disease is still limited to the ovaries 
(Goff et al., 2000).
These symptoms are, however, shared with many more common gastrointestinal, 
genitourinary and gynecological conditions and have not yet proved useful for 
early diagnosis. Metastases can occur through lymphatics to nodes at the renal 
hilus or through blood vessels to the parenchyma of the liver or lung. Most 
frequently, small clusters of cancer cells are shed by the ovary and implant on the 
peritoneal surface, forming numerous nodules. For cancer in the ovary, unlike 
cancers at many other sites, no anatomical barrier exists to widespread metastasis 
throughout the peritoneal cavity.
Although OvCa risk is, at least in part, influenced by hormonal, environmental 
and racial factors, a major role is played by genetic factors. Indeed, a key advance 
in the study of OvCa etiology has been the identification of mutations in the 
BRCA genes. BRCA1 and BRCA2 genes act as tumor suppressor genes and, when 
mutated, are associated with the accumulation of chromosomal abnormalities and 
thus with a higher risk of developing cancer. Inheritance of mutations in BRCA 
genes is associated with a 27% to 44% lifetime risk of OvCa. A higher incidence 
of carcinomas of the ovary has also been detected in families affected by the 
HNPCC syndrome (Watson and Lynch, 1993), which is caused by mutations in 
DNA MMR genes. HNPCC carriers account for approximately 1% of OvCa 
patients, and their estimated lifetime risk of OvCa is 9% to 12% (Rubin et al., 
1998). Mutations in BRAF, KRAS and ERBB2 oncogenes and in the tumor 
suppressor PTEN have been found in a large subset of OvCa (Singer et al., 2003;
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Nakayama et al., 2006). The inactivation of PTEN and an activating mutation of 
KRAS are sufficient to induce ovarian endometrioid carcinoma in a mouse model 
(Dinulescu et al., 2005). Furthermore, mutations of CTNNB1 have been detected 
both in ovarian carcinomas and in their precursor lesions (Oliva et al., 2006). 
Indeed, inactivation of the WNT/CTNNB1 and the PI3K/PTEN pathways has 
been shown to induce the development of endometrioid carcinoma in an 
engineered mouse model (Wu et al., 2007). The small G-protein RAB25, which 
regulates motility, aggressiveness, apoptosis and autophagy, and mediates 
survival in response to stress, has also been found up-regulated in the majority of 
OvCa (Cheng et al., 2005). The Aurora-A kinase (Aurora-A) is associated with 
tumor initiation and progression and is overexpressed in various malignancies. 
Inhibition of Aurora-A induces cell cycle arrest and decreases proliferation of 
epithelial OvCa stem cells, which represent the chemoresistant population and act 
as a source of recurrence (Chefetz et al., 2011). All of these and several other 
amplified oncogenes are potential targets for OvCa therapy.
Recent attention has focused on the role that the surrounding microenvironment 
plays in the process of tumorigenesis as well as tumor progression and how it 
contributes to tumor biology (Harris, 2002; Hockel and Vaupel, 2001). Ovarian 
carcinoma cells leaving the primary tumor may therefore experience lower 
oxygen levels (Mutch and Williams, 1994). Evidences exist that 
microenvironmental hypoxia and aggressively invasive phenotypes are observed 
in ovarian carcinomas (Imai et al., 2003). HIF-1 alpha overexpression is 
associated with a poor prognosis in patients with OvCa (Osada et al., 2007),
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suggesting that hypoxia is important for the acquisition of aggressive behavior in 
OvCa. In contrast with endometrial- and cervical carcinoma, a consistent 
significant correlation between tumor stage, grade and HIF-1 alpha expression 
has been described for ovarian carcinoma. HIF-1 alpha expression was 
significantly higher in tumors of FIGO stages III and IV than in those of stages I 
and II (Acs et al., 2004). With larger tumor bulk in the high stage tumors and 
subsequent areas of hypoxia this is as expected. HIF-1 alpha expression was also 
significantly higher in grade 1 OvCa compared with grade 3 tumors (Bimer et al., 
2001).
1.3.2 Actual therapy and drug resistence
Adjuvant chemotherapy improves both overall and progression-free survival in 
all patient subgroups, although it is expected to have a greater effect in patients 
who are optimally debulked. Evidence from several randomized controlled 
clinical trials has now established the platinum-paclitaxel combination regimen 
as first-line treatment for advanced OvCa, yielding response rates of over 80% 
and 40-60% complete responses (Agarwal and Kaye, 2003; Bimer et al., 2001; 
Ozols et al., 2003; Sandercock et al., 2002). However, most of these patients will 
eventually relapse with a median progression-free survival of 18 months 
(Sandercock et al., 2002). At relapse, patients might be treated with the same 
dmgs, with response rates that are proportional to their treatment-free interval 
(Gore et al., 1990). The length of the disease-free period following response to
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platinum compounds can be used to categorize patients into groups with different 
prognoses: platinum-sensitive disease, platinum-resistant disease and platinum- 
refractory disease. Although the response rate of platinum-sensitive disease to the 
single agent carboplatin is greater than 50%, the response rate to carboplatin is 
only 10-20% for platinum-resistant disease and less for platinum-refractory 
disease. These two groups of patients are therefore usually treated with other 
agents, such as liposomal doxorubicin, gemcitabine, topotecan, etoposide and 
hormonal therapies. However, the response rates to treatment decrease with each 
subsequent relapse following the development of drug resistance. One of the 
major disappointments in the field of OvCa research is the failure of currently 
established therapies to induce a cure at diagnosis, even in chemosensitive 
tumors. Efforts have been made to cure OvCa over the past decade using 
different classes of chemotherapy agents in various combinations, dosages and 
schedules to overcome chemoresistance. Multiple studies in OvCa have 
established associations between both microvessel density and VEGFa levels in 
primary tumors and the extent of disease, time to progression and overall survival 
after initial anti-angiogenic therapy (Burger, 2007). In addition, the VEGF 
pathway is implicated in preclinical models of ascites formation (Nagy et al., 
1995; Yoshiji et al., 2001). Anti-angiogenic agents are currently moving from 
Phase II to Phase III clinical trials in OvCa. In the recurrent disease setting, two 
Phase II studies of BV by Cannistra et al. and Burger et al. yielded response rates 
of 15% and 25% respectively (Cannistra et al., 2007; Burger et al., 2007). 
Progression-free survival rates at 6 months of 28% and 40% were particularly
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encouraging; notably, 84% and 42% of the patients treated had platinum resistant 
disease. The EGFR is overexpressed in 70% of OvCa and associated with 
advanced disease at presentation, poor prognosis and chemoresistance (Bartlett 
et al., 1996; Fischer-Colbrie et al., 1997). Preclinical studies suggested that 
inhibiting this target might have anti-tumor activity and reverse chemoresistance 
(Sirotnak, 2003; Ciardiello et al., 2000).
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1.4: PROSTATE CANCER
1.4.1 An asymptomatic disease
PCa is a multifocal disease that requires androgens for development and finally 
develops into solid tumors. In prostate tissue, androgens are involved in 
differentiation, development and normal functioning (Culig and Bartsch, 2006). 
Initial stages of erroneous PCa growth can be controlled by reducing the 
availability of androgens to the prostate cells (Huggins and Hodges, 2002). 
However, overtime PCa cells attain androgen independence.
Though there are many different ways leading to progression of cancer and 
ultimately to androgen-independent cancer (Asirvatham et al., 2006), 
mechanisms underlying the emergence to an androgen receptor (AR)- 
independent aggressive PCa are not completely understood.
Tumor microenvironment usually consists of disorganized and hemorrhagic 
vasculature (Carmeliet and Jain, 2000; McDonald and Choyke, 2003), which can 
lead to low oxygen (hypoxia) and nutrient supply to cells. Clinical studies with 
withdrawal of androgens have demonstrated reduction in hypoxia in tumor 
regions of PCa patients (Milosevic et al., 2007), suggesting that hypoxia may be 
involved in the development of androgen independence in these patients, 
however, mechanisms for this androgen independence have not been identified. 
Interestingly, HIF-1 alpha has been found to be overexpressed in PCa even in non 
hypoxic conditions and signaling pathways, commonly induced in cellular stress
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like JNK and MAPK have been implicated in the activation and control of HIF-1 
alpha in cancer (Berra et al., 2000; Baek et al., 2001). In PCa, p38 has been 
implicated in androgen-independent progression of PCa (Shida et al., 2007).
Both p38 and its active form phospho p38, as well as some upstream kinases 
(PAK1, MKK6, MKK4), are overexpressed in human cancerous prostatic 
epithelium (Ricote et al., 2006; Royuela et al., 2002; Uzgare et al., 2003). Uzgare 
et al. using a transgenic mouse model for PCa, described that phospho p38 is 
overexpressed in prostatic intraepithelial neoplasia (PIN), well-differentiated and 
moderately differentiated cancers while was reduced or absent in late-stage 
adenocarcinomas and metastatic deposits. However, like in other tissues, studies 
focused on p38 function in the prostate malignancy reveal that this MAPK can 
elicit multiple and even opposite responses, which seem to vary depending on the 
cell system and context. A proapoptotic role for p38 has been established in a 
number of PCa in vitro models and conditions. p38 promotes apoptosis induced 
by 2-methoxyestradiol (Shimada et al., 2006), melatonin (Joo and Yoo, 2009), 
proanthocyanidins (Vayalil et al., 2004), raloxifene (Zhang and Kong, 2008), 
carprofen (Khwaja et al., 2008), or protoapigenone (Chang et al., 2008). By 
contrast, p38 exerts a protective effect in TNF-induced apoptosis in PCa cells 
(Ricote et al., 2006). In spite of having a prominent proapoptotic role p38 may 
contribute to PCa progression by promoting tumor growth, androgen 
independence acquisition, and metastasis. It has been proposed that IL-6 may 
support androgen-independent tumor growth by enhancing AR 
expression/activity. Lin and colleagues (Lin et al., 2001) demonstrated that, in
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turn, the IL-6-induced androgen response depends on p38 activity. Huang and 
colleagues (Huang et al., 2005) showed in PC3 cells that p38 is necessary for 
TGF-beta-mediated activation of MMP-2 and cell invasion in PCa. Moreover, 
p38 has been involved in the invasion and migration abilities of the PCa DU145 
cells, by enhancing the expression of MMPs-2 and -9, and urokinase-type 
plasminogen activator (u-PA) (Shen et al., 2010; Xu et al., 2009) also described 
MKK4 as a regulator and activator of MMP-2. In agreement, Tang and Lu (Tang 
and Lu, 2009) found that p38 activity contributes to adiponectin induced integrin 
expression and migration capability of human PCa cells. Therefore, and in spite 
of displaying proapoptotic functions, p38 may constitute a target for PCa 
treatment given its demonstrated contribution to some PCa hallmarks, as 
androgen dependence and metastatic phenotype acquisition (Huang et al., 2005).
1.4.2 Actual therapy and drug resistance
Along with surgery or radiation therapy, hormonal therapy is a main mode of 
PCa treatment. For men with metastatic disease, chemotherapy provides a 
significant survival advantage. Therefore, new treatment options are being 
actively pursued to extend the survival of metastatic cancer patients. Androgen 
and AR are required for normal prostate development and carcinogenesis. 
Castration-resistant PCa tissues express AR and remain responsive to low levels 
of androgens. AR mutation, truncation and/or amplification may confer 
differential ligand and antagonist affinity and specificity. Thus, even low levels
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of testosterone could still activate the AR and confer the growth and survival 
advantages for PCa cells. Several studies have demonstrated that low levels of 
testosterone are present in PCa cells. Mohler and colleagues studied testosterone 
levels in clinical specimens collected from castrated patients who underwent 
prostatectomy and found that intratumoral testosterone levels were elevated 
despite an overall reduction in serum testosterone (Petrylak, 2011). Abiraterone 
and orteronel are specific inhibitors of 17,20 lyase, which inhibit the conversion 
of 17-alpha-hydroxyprogesterone to androstenedione. Treatment with abiraterone 
was associated with a 35% reduction in death from PCa with an improvement in 
median survival from 10.9 to 14.8 months (de Bono et al., 2011), while in a phase 
I/II study of orteronel, of 43 patients with RECIST-evaluable disease, 6 showed a 
partial response, 23 had stable disease, and 9 showed progression (Massard and 
Fizazi, 2011). Phase III clinical trials with Orteronel are currently in progress in 
chemotherapy naive and post-docetaxel settings. MDV3100 antagonizes AR 
action by preventing the translocation of the AR from cytoplasmic to nuclear 
compartment and by inhibiting DNA binding of AR and hence repressed the 
expression of androgen-regulated genes. In a phase I study of docetaxel-naive 
and docetaxel-treated patients, 62% and 51% of patients, respectively, had at 
least a 50% PSA decline (Scher et al., 2010). One unique feature of the androgen- 
independent PCa cells is that the regression of prostate tumors still requires an 
activation of apoptotic machinery. In many cases, AR blocking is capable of 
inducing apoptosis. Clusterin is a antiapoptotic protein expressed in prostate, 
kidney, bladder, ovarian, lung, colorectal, and breast cancers. Clusterin
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expression increases with Gleason score, and is upregulated after androgen 
blockade (July et al., 2002; Miyake et al., 2000). Clusterin modulates resistance 
to androgen blockade, radiation therapy, and chemotherapy. OGX-011 
(Custirsen) is an investigational antisense compound that downregulates clusterin 
expression and enhances apoptotic death of PCa cells (Chi et al., 2008).
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1.R: AUTOPHAGY AND APOPTOSIS IN CANCER
1.R.1 Two pathways linked together
Autophagy, a process long known to provide a survival advantage to cells 
undergoing nutrient deprivation or other stresses (Lum et al., 2005), has also been 
more recently linked to cell death process (Levine and Yuan, 2005). Thus, 
apoptosis is not the sole means by which the cell can undergo a genetically 
programmed regulated process leading to self-elimination (Ouyang et al., 2012). 
Cell death can occur by several mechanisms and the phenotypic changes that 
accompany cell death can vary depending on the stimulus and cell types. In any 
given death scenario, the cell decides which pathway to use, depending on the 
nature of the stimulus and the particulars of the cell environment. Furthermore, 
apoptosis and autophagy are not mutually exclusive pathways. They have been 
shown to act in synergy and also to counter each other. Three different types of 
interplay have come to light, each of which is equally valid for a particular cell 
type, stimulus and environment. Both apoptosis and autophagy can act as partners 
to induce cell death in a coordinated or cooperative manner; autophagy acts as an 
antagonist to block apoptotic cell death by promoting cell survival, or autophagy 
acts as enabler of apoptosis, participating in certain morphologic and cellular 
events that occur during apoptotic cell death, without leading to death in itself. 
One of the major clues today is the comprehension of the crosstalk between 
autophagy and apoptosis in tumor development (Todde et al., 2009). Recently, it
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has been shown that both cFLIP and vFLIP of Kaposi’s sarcoma-associated 
herpesvirus, in addition to inhibiting apoptosis mediated by death receptors, 
suppress autophagy by preventing ATG3 from binding and processing 
MAP1LC3 (LC3) (Lee et al.,2009). These findings identify another negative 
regulatory step common to autophagy and apoptosis, besides the antiapoptotic 
BCL2 family proteins, which can play a fundamental role facilitating the early 
stages of oncogenesis. In many cases, chemotherapy- and metabolic stress 
triggering apoptosis induced activation of the autophagic pathway, contributing 
to the survival of formed tumors, thereby favoring resistance. It is clear that the 
introduction in tumor therapy of autophagy inhibitors, in combination with 
therapies designed to induce apoptosis in human cancers, appears a rationale end 
in the tumor treatments.
1.R.2 Autophagy
Cellular homeostasis requires a constant balance between biosynthetic and 
catabolic processes. Eukaryotic cells primarily use two distinct mechanisms for 
large-scale degradation, the proteasome and autophagy; but only autophagy has 
the capacity to degrade entire organelles. The three types of autophagy are 
macroautophagy, microautophagy, and chaperone-mediated autophagy 
(Klionsky, 2004).
Autophagy plays an important physiological role in human health. During 
autophagic process, a double- or multimembrane-bound structure, called the
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autophagosome or autophagic vacuole, is formed de novo to sequester cytoplasm. 
Then, the vacuole membrane fuses with the lysosome to deliver the contents into 
the organelle lumen, where they are degraded and the resulting macromolecules 
recycled (Nair and Klionsky, 2005) (Figure3).
Autophagy occurs at basal levels in most tissues and contributes to the routine 
turnover of cytoplasmic components. However, autophagy can be induced by a 
change of environmental conditions such as nutrient depletion. In addition to 
turnover of cellular components, autophagy is involved in development, 
differentiation, and tissue remodeling in various organisms (Levine and Klionsky, 
2004).
Autophagy is also implicated in different human diseases. Paradoxically, 
autophagy can serve to protect cells (Boya et al., 2005) but may also contribute to 
cell damage. This pathway is involved in programmed cell death (PCD). Type I 
PCD, apoptosis, is characterized by condensation of cytoplasm and chromatin, 
DNA fragmentation, and cell fragmentation into apoptotic bodies, followed by 
removal and degradation of the dying cells by phagocytosis (Galluzzi et al., 
2012). Type II PCD is characterized by the accumulation of autophagic vesicles 
(autophagosomes and autophagolysosomes) and is often observed when massive 
cell elimination is demanded or when phagocytes do not have easy access to the 
dying cells (Galluzzi et al., 2012). One feature that distinguishes apoptosis from 
autophagic cell death is the source of the lysosomal enzymes used for most of the 
dying cells' degradation. Apoptotic cells use phagocytic cell lysosomes for this 
process, whereas cells with autophagic morphology use the dying cells'
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Figure 3. Autophagic pathway. Both metabolic stress and cancer therapies 
activate signalling pathways that stimulate autophagy. The process involves the 
sequestration of cytoplasmic material by a membrane-bound vesicle called the 
autophagosome, which then fuses with a lysosome to form an autolysosome. The 
degradation of cytoplasmic material within the autolysosome can promote cell 
survival either by generating free fatty acids and amino acids, which can be 
reused by the cell to maintain energy production and protein synthesis, or by 
removing harmful proteins and organelles. It can also promote cell death 
independently (presumably through self-cannibalization) or together with 
apoptosis. Furthermore, the turnover of proteins and organelles by autophagy 
may contribute to the control of cell growth (Levine, 2007).
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lysosomal machinery. It has been unclear whether autophagy directly executes 
cell death or is the secondary effect of apoptosis. Recently has been shown that 
type I PCD and type II PCD are probably nonexclusive mechanisms in 
mammals, because they are sometimes observed in the same dying cell 
(Gonzalez-Polo et al., 2005).
Autophagy is controlled by molecules that fall into two categories: sensors and 
effectors. Effectors can be further divided into type-I and type-II effectors. Type-I 
effectors are involved in the steps (nucleation, expansion, uncoating and 
completion) leading to the formation of autophagosomes from the 
preautophagosomal membrane or phagophore (Nair and Klionsky, 2005). Type-I 
effectors are represented by the generally evolutionarily conserved ATG proteins 
and PI3K, the ortholog of yeast Vps34. The activity of type-I effectors is 
regulated by the formation of a class III PI3K-ATG6 (BECLIN1) complex, 
(Kihara et al., 2001a; Kihara et al., 2001b) and ubiquitin-like conjugation systems 
(the ATG8/LC3 and ATG12 systems) (Mizushima et al., 1998; Kabeya et al., 
2000; Tanida et al., 2002). One type-I effector, BECLIN1, is a tumor suppressor 
gene product. Monoallelic deletion of this effector is observed in 40 to 75% of 
sporadic ovarian and breast cancers (Aita et al., 1999; Liang et al., 1999). 
Recently, transgenic mouse models have shown that monoallelic deletion of 
BECLIN1 promotes tumor development in various tissues (Qu et al., 2003; Yue et 
al., 2003). Type-II effectors are involved in the maturation of autophagosomes 
(e.g., Lamp-2, RAB proteins, SNAREs, SKD1) (Darsow et al., 1997; Nara et al., 
2002; Jager et al., 2004; Eskelinen et al., 2004; Ishihara et al., 2001). Sensors
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comprise the diverse signaling pathways, second messengers and protein kinase 
complexes that respond to environmental changes, and regulate the steps in 
autophagosome formation that occur upstream of the effectors. Many sensors 
involved in autophagy signaling are tumor suppressor gene products [e.g., 
phosphatase and PTEN, TSC1-TSC2, p53, death associated protein kinase 
(DAPk) and oncogenes (e.g., AKT, Ras)]. These sensors are not specific for 
autophagy, but are also implicated in pathways that control a variety of cell 
functions. Thus, the signaling pathways that regulate autophagy form part of a 
cell program that is altered in cancer cells. Autophagy is believed to have an 
important role in tumor development. When baseline levels were compared, the 
amount of proteolysis or autophagic degradation in cancer cells was less than that 
of their normal counterparts (Gunn et al., 1977; Kisen et al., 1993; Kirkegaard et 
al., 2004). In these studies, the rate of degradation of long-lived proteins was 
considered the standard index for measuring autophagy. Other studies also 
reported that cells that were transformed by simian virus 40 (SV40) or treated 
with a carcinogen, underwent decreased levels of proteolysis compared with non­
transformed or non-treated cells. This indicates a link between carcinogenesis and 
decreased levels of autophagy (Otsuka and Moskowitz, 1978; Schwarze and 
Seglen, 1985). Conversely, under conditions of nutrient deprivation, induction of 
the autophagic pathway is not downregulated in transformed epithelial cells 
compared with normal epithelial cells (Lee et al., 1992). Although autophagy is 
suppressed during the early stages of tumorigenesis, it seems to be upregulated 
during the later stages of tumor progression as a protective mechanism against
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stressful conditions (Ogier-Denis and Codogno, 2003; Gozuacik and Kimchi, 
2004; Cuervo, 2004). As the tumor grows, cancer cells at the periphery (close to 
blood vessels) continue to proliferate by maintaining anabolism (Cuervo, 2004). 
On the other hand, cancer cells that are located in the central areas of the tumor 
are poorly vascularized, so the induction of autophagy allows them to survive in 
these low-nutrient and low oxygen conditions (Cuervo, 2004). Autophagy can 
promote cell adaptation and survival, but under some conditions it leads to cell 
death. A number of studies have reported that autophagy, or autophagic cell 
death, is activated in cancer cells that are derived from tissues such as breast, 
colon, prostate and brain, in response to various anticancer therapies (Bursch et 
al., 1996; Paglin et al., 2001; Yao et al., 2003; Opipari, Jr. et al., 2004). 
Unfortunately, the autophagic response of cancer cells to therapeutics is not 
always an indication of cell death. Infact, inhibitors of autophagy can produce 
different outcomes, cell growth or cell death, that highlight the need to elucidate 
the mechanisms of autophagy, and its inhibition (Bursch et al., 1996; Yao et al., 
2003; Bursch et al., 2000; Kanzawa et al., 2004; Bursch et al., 2000). It will be 
important for clinical oncologists and cancer researchers to determine which 
cancer cell types most commonly undergo autophagy in response to therapy, and 
whether increased autophagy is a sign of drug responsiveness or resistance.
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1.R.3 Apoptosis
Apoptosis is a genetically controlled form of cell death that is essential for tissue 
remodeling during embryogenesis and for maintenance of the homeostatic 
balance of cell numbers later in adult life. Although multiple forms of cell death 
have been described (Galluzzi et al., 2012), apoptosis is characterized by 
morphological changes including cell shrinkage, membrane blebbing, chromatin 
condensation and nuclear fragmentation, loss of microvilli, and extensive 
degradation of chromosomal DNA (Galluzzi et al., 2012) (Figure 4). In general, 
the apoptotic program can be subdivided into three phases: the initiation phase, 
the decision/effector phase, and the degradation/execution phase. In the initiation 
phase, signal transduction pathways that are responsive to external stimuli, such 
as death receptor ligands, or to internal conditions, such as that produced by DNA 
damage, are activated (Lazebnik et al., 1993; Solary et al., 1993). During the 
ensuing decision/effector phase, changes in the mitochondrial membrane occur 
that result in disruption of the mitochondrial membrane potential and ultimately 
loss of mitochondrial membrane integrity (Wang, 2001). A key event in the 
decision/effector phase is the release of cytochrome c into the cytoplasm (Wang, 
2001) and activation of proteases and nucleases that signal the onset of the final 
degradation/execution phase. An important concept in understanding apoptosis is 
that the mitochrondrion is a key target of apoptotic stimuli and disruption of 
mitochondrial function is central to subsequent events that lead to degradation of 
vital cellular components (Wang, 2001). When the apoptotic machinery is
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Figure 4.Signalling pathways in apoptosis. A simplified scheme of apoptotic 
pathway. Here are indicated both intrinsic and extrinsic pathways. However, both 
are convergent on mitochondria, with the final result of cytochrome C extrusion 
from the membranes (Cotter, 2009).
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triggered in response to a wide range of death stimuli that are generated from 
within the cell, such as oncogene activation and DNA damage, the authors refer 
to this event as "intrinsic pathway". The inactivation of this pathway is generally 
regarded as a hallmark of cancer (Hanahan and Weinberg, 2000). Conversely, the 
extrinsic pathway is initiated by the binding of an extracellular death ligand, 
such as FASL, to its cell-surface death receptor, such as FAS (Nagata, 1999). In 
both cases, the critical downstream effectors are the caspases, and these are 
considered the engine of apoptotic cell death (Mittl et al., 1997). Although the 
first mammalian caspase (caspase-1) was identified as an important regulator of 
the inflammatory response (Thomberry et al., 1992; Cerretti et al., 1992) at least 
7 of the 14 known mammalian caspases have important roles in apoptosis (Shi, 
2002; Eamshaw et al., 1999). The apoptotic caspases are generally divided into 
two classes: the initiator caspases, which include caspase- 2, -8, -9 and -10 and 
the effector caspases, which include caspases-3, -6 and -7. They are synthesized 
in the cells as inactive enzymes that must be processed by proteolytic cleavage at 
aspartic acid residues (Shi, 2002). The activated proteases cleave other proteins 
by recognizing an aspartic acid residue at the cleavage site and are consistent 
with an auto- or transcleavage processing mechanism for activation when 
recruited to activated death receptors. Importantly, biochemical studies support 
the notion of a caspase hierarchy that consists of initiators and effectors that are 
activated in a cascade fashion. Initiator caspases such as caspase-8 and -9 are 
activated directly by apoptotic stimuli and function, in part, by activating effector 
caspases such as caspase-3, -6, and -7 by proteolytic cleavage (Shi, 2002). It is
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the effector caspases that result in highly specific cleavage of various cellular 
proteins and the biochemical and morphological degradation associated with 
apoptosis. In 1996 Liu and colleagues (Liu et al., 1996) showed that the release of 
cytochrome c from the mitochondrion was crucial for the execution of the 
apoptotic pathway because it activated caspase 9, which in turn activated caspase 
3. Yang and colleagues showed that BCL2 suppressed this release of cytochrome 
c30 and therefore prevented caspase activation. BCL2 was the first protein 
involved in the regulation of apoptosis to be molecularly characterized. The 
BCL2 gene was originally identified by Yoshide Tsujimoto (Tsujimoto et al., 
1984). During the 1990s, membership of the BCL2 family grew and the proteins 
discovered fell into one of three subfamilies. Proteins such as BCL-XL (also 
known as BCL2L1) (Boise et al., 1993), BCL-W (Gibson et a l, 1996) and MCL1 
(Kozopas et al., 1993) all contain three or four BCL2 homology (BH) domains, 
which are required for their antiapoptotic function. These domains drive 
interactions with other BCL2 family members, particularly at the level of the 
mitochondrion, where they regulate the release of proapoptotic mediators, such as 
SMAC (also known as DIABLO) (Du et al., 2000; Verhagen et al., 2000). The 
second subfamily consists of proapoptotic members, such as BAX (Oltvai et al., 
1993) and BAK (Chittenden et al., 1995), which can form pores or interact with 
pore forming proteins at the level of the mitochondrial membrane, a function that 
is antagonized by BCL2. The discovery of a third BCL2 subfamily, which 
consists of proteins that have only a short BH3 domain, was important because 
these proteins provided a link between the terminal effector process and the
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signalling network that informs the cell of its status regarding events such as 
growth factor stimulation, redox balance, DNA integrity, cell attachment and 
microtubule function. Although BCL2 was originally identified as a crucial factor 
in the development of B cell lymphomas, it also plays an important part in other 
tumors. In addition to activation of BCL2 by chromosomal translocations in 
cancer, increased BCL2 expression is found in other tumors, such as non 
Hodgkin’s lymphomas and certain lung cancers (Monni et al., 1997; Ikegaki et 
al., 1994). Since these discoveries, several other mechanisms have been identified 
that can lead to increased BCL2 expression, including hypermethylation of BCL2 
and loss of micro rRNAs that normally downregulate BCL2 expression (Hanada 
et al., 1993; Cimmino et al., 2005). For example, the transcription factor p53 is 
mutated in most human cancers, and some of its direct targets include BAX, BID 
and the BH3-only proteins PUMA and NOXA, all of which are pro-apoptotic 
members of the BCL2 family (Miyashita and Reed, 1995; Oda et al., 2000; Sax et 
al., 2002; Nakano and Vousden, 2001). Any impairment of p53 function leads to 
deregulation of apoptosis signalling pathways and increases tumorigenesis.
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1.6: SIGNAL-TRANSDUCTION PATHWAYS REGULATING THE
AUTOPHAGY/APOPTOSIS BALANCE: THE ROLE OF p38 ALPHA
1.6.1 p38 family
Cellular behavior in response to extracellular stimuli is mediated through 
intracellular signaling pathways such as MAPK (Rouse et al., 1994). MAPK are 
members of discrete signaling cascades and serve as focal points in response to a 
variety of extracellular stimuli. Four distinct subgroups within the MAPK family 
have been described: (1) extracellular signal-regulated kinases (ERKs), (2) c-JUN 
N-terminal or stress-activated protein kinases (JNK/SAPK), (3) ERK/ big MAP 
kinase 1 (BMK1), and (4) the p38 group of protein kinases. p38 alpha (p38) was 
first isolated as a 38-kDa protein rapidly tyrosine phosphorylated in response to 
lipopolysaccharide (LPS) stimulation (Han et al., 1993; Han et al., 1994). p38 
cDNA was also cloned as a molecule that binds puridinyl imidazole derivatives 
which are known to inhibit biosynthesis of inflammatory cytokines such as IL1 
and TNF in LPS stimulated monocytes (Lee et al., 1994). To date, four splice 
variants of the p38 family have been identified: p38 alpha, p38 beta (Jiang et al., 
1996), p38 gamma (ERK6, SAPK3) (Lechner et al., 1996; Li et al., 1996), and 
p38 delta (SAPK4) (Jiang et al., 1997; Kumar et al., 1997). Sequence 
comparisons have revealed that each p38 isoform shares -60% identity within the 
p38 group but only 40-45% to the other three MAPK family members.
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The four p38 isoforms are encoded by different genes and have significant levels 
in most cell types, whereas the others seem to be expressed in a more tissue- 
specific manner; for example, p38 beta in brain, p38 gamma in skeletal muscle 
and p38 delta in endocrine glands. p38 family members have overlapping 
substrate specificities, albeit some differences have been reported, with particular 
substrates being better phosphorylated by p38 alpha and p38 beta than p38 
gamma and p38 delta or vice versa (Cuenda and Rousseau, 2007). The genetic 
ablation of specific p38 members has also demonstrated the existence of 
functional redundancy.
1.6.2 Activation of p38
First described in 1994, the p38 cascade regulates a variety of cellular responses 
to stress, inflammation and other signals (Han et al., 1994;(Lee et al., 1994). As 
in many other protein kinases, the activation of p38 isoforms requires 
phosphorylation on a flexible loop termed the phosphorylation lip or activation 
loop. These phosphorylations induce conformational reorganizations that relieve 
steric blocking and stabilize the activation loop in an open and extended 
conformation, facilitating substrate binding. p38 members are activated by dual 
phosphorylation in the activation loop sequence Thr-Gly-Tyr. In response to 
appropriate stimuli, threonine and tyrosine residues can be phosphorylated by 
three dual specificity MKKs. MKK6 can phosphorylate the four p38 members, 
whereas MKK3 activates p38 alpha, p38 gamma and p38 delta, but not p38 beta.
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Both MKK3 and MKK6 are highly specific for p38 (Enslen et al., 1998; Alonso 
et al., 2000). Furthermore, p38 alpha can be also phophorylated by MKK4, an 
activator of the JNK pathway (Doza et al., 1995; Brancho et al., 2003). In 
addition, several studies including genetic analysis in mice have demonstrated 
functional differences between MKK3 and MKK6 (Zhang et al., 2007). 
Depending on the stress stimulus, MKK3 and MKK6 also contribute to different 
extents to the activation of other p38 members (Remy et al., 2010). In addition to 
the activation by upstream kinases, there is a MKK independent mechanism of 
p38 activation involving TGF beta-activated protein kinase 1 (TAKl)-binding 
protein (TAB1) (Ge et al., 2002). The activation of p38 in this pathway is 
achieved by the autophosphorylation of p38 alpha after interaction with TAB1. 
Although there is an indication that TAB 1-dependent p38 phosphorylation occurs 
in LPS, TNF, and CpG treated B cell lines, a study using MKK3/6 knockout 
mouse embryonic fibroblast (MEF) cells showed that TNF-induced p38 
activation is solely dependent on MKKs (Brancho et al., 2003).
1.6.3 Inactivation of p38
Under physiological conditions, p38 activation is often transient despite the 
unchanging level of p38 throughout the course of stimulation. 
Dephosphorylation, then, would seem to play a major role in the downregulation 
of p38 activity. Many dual-specificity phosphatases have been identified that act 
upon various members of the p38 pathway and are grouped as the MAPK
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phosphatase (MKP) family (Sun et al., 1993). Several members can efficiently 
dephosphorylate p38 alpha and p38 beta (Camps et al., 1998; Muda et al., 1996); 
however, p38 gamma and p38 delta are resistant to all known MKP family 
members. In addition, other types of phosphatases such as serine/threonine 
protein phosphotase type 2C (PP2C) has been shown to have a role in 
downregulating the MAPK HOG1 pathway as well as negatively regulating 
human MKK6 and MKK4 levels in vitro and in vivo (Maeda et al., 1994; Posas et 
al., 1996; Takekawa et al., 1998). Taken together, these results suggest a 
mechanism by which p38 isoforms are differentially regulated depending on 
phosphatase levels and specificity.
1.6.4 Targets of p38
It has been estimated that p38 may have approx. 200-300 substrates each. 
Accordingly, p38 have been reported to phosphorylate a broad range of proteins, 
both in vitro and in vivo. Much of the information about p38 substrates comes 
from the use of chemical inhibitors. On the basis of their functions, p38 alpha 
substrates comprise protein kinases implicated in different processes, nuclear 
proteins, including transcription factors and regulators of chromatin remodelling, 
and a heterogeneous collection of cytosolic proteins that regulate processes as 
diverse as protein degradation and localization, mRNA stability, endocytosis, 
apoptosis, cytoskeleton dynamics or cell migration (Figure 5). The first p38 alpha 
substrate identified was the MAPK-activated protein kinase 2 (MAPKAPK2 or
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MK2) (Rouse et al., 1994; Freshney et al., 1994; McLaughlin et al., 1996). This 
substrate, along with its closely related family member MK3, were both shown to 
activate various substrates including small heat shock protein 27 (HSP27) 
(Stokoe et al., 1992), lymphocyte-specific protein 1 (LSP1) (Huang et al., 1997), 
CREB (Tan et al., 1996), transcription factor ATF1 (Tan et al., 1996), serum 
response factor (SRF) (Heidenreich et al., 1999), and tyrosine hydroxylase 
(Thomas et al., 1997). More recently, MK2 has been found to phosphorylate 
tristetraprolin (TTP), a protein that is known to destabilize mRNA hinting at a 
role for p38 in mRNA stability (Mahtani et al., 2001). p38 regulated/activated 
kinase (PRAK) is a p38 alpha and/or p38 beta activated kinase that shares 20- 
30% sequence identity to MK2 and is thought to regulate HSP27 (New et al.,
1998). Mitogen- and stress-activated protein kinase-1 (MSK1) can be directly 
activated by p38 and ERK, and may mediate activation of CREB (Deak et al., 
1998; New et al., 1999). A large number of cytosolic proteins can be 
phosphorylated by p38 members, including phospholipase A2, the 
microtubuleassociated protein tau, Na+/H+ exchanger 1 (NHE-1), cyclin D l, 
cyclin-dependent kinase inhibitors (CDKI), BCL2 family proteins, growth factor 
receptors or keratins (Ono and Han, 2000; Cuenda and Rousseau, 2007; Shi and 
Gaestel, 2002). The p38 pathway is an important regulator of protein turnover. 
For example, short isoform of FLIP is an inhibitor of TNF alpha-induced 
apoptosis whose proteasome-mediated degradation is regulated by p38 
phosphorylation. A recent report has proposed that p38 alpha inhibits the 
lysosomal degradation pathway of autophagy by interfering with the intracellular
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trafficking of the transmembrane protein ATG9. This would be mediated by p38 
alpha-interacting protein (p38IP), which was found to bind to ATG9, facilitating 
starvation-induced ATG9 trafficking and autophagosome formation (Webber and 
Tooze, 2010). How exactly p38 alpha might regulate the p38IP-ATG9 
interaction and whether this is the only link between the p38 pathway and 
autophagy remains to be elucidated. Additional examples of p38 substrates are 
the fibroblast growth factor receptor 1 (FGFR1) and the ARE-binding and 
mRNA-stabilizing protein human antigen R HuR. FGFR1 can be translocated 
from the extracellular space into the cytosol and nucleus of target cells, and 
regulates processes such as rRNA synthesis and cell growth. FGFR1 
translocation requires p38 activation, which phosphorylates the C-terminal tail of 
FGFR1 on Ser777. Interestingly, the mutation S777A abolishes FGFR1 
translocation, whereas phosphomimetic mutants bypass the requirement for 
active p38 for translocation (Sorensen et al., 2008). In the case of HuR, a new 
direct link with p38 family has been established recently in the G1 cell-cycle 
arrest induced by gamma-radiation (Lafarga et al., 2009). When cells are 
irradiated, p38 alpha is transiently activated and phosphorylates HuR on Thrll8 , 
which results in HuR cytoplasmic accumulation and enhanced binding to the 
p21Cipl mRNA. HuR binding increases p21Cipl mRNA stability, therefore 
allowing the expression of the appropriate p21Cipl protein levels required for G1 
cell-cycle arrest (Lafarga et al., 2009). Many transcription factors are 
phosphorylated and activated by p38 isoformss in response to different stimuli. 
Classical examples include ATF1, 2 and 6, SRF accessory protein 1 (Sapl),
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CHOP [C/EBP (CCAAT/enhancer-binding protein)-homologous protein], p53 
and myocyte enhancer factor 2 (MEF2C and MEF2A) (Shi and Gaestel, 2002). 
Recent results have established a role for p38 alpha in the regulation of lineage 
choices during myelopoiesis through phosphorylation of C/EBP alpha on Ser21 
(Geest et al., 2009). A core network of 16 transcription factors has also been 
recently proposed to mediate the regulation by p38 alpha of human squamous 
carcinoma cell quiescence (Adam et al., 2009). In addition, p38 dependent 
phosphorylation of the transcription factor upstream stimulatory factor 1 (USF1) 
on Thrl53 has been reported to facilitate acetylation, which in turn changes the 
gene regulatory properties of USF1 (Corre et al., 2009). p38 isoforms are 
emerging as important modulators of gene expression by regulating chromatin 
modifiers and remodellers (Simone, 2006). The promoters of several genes 
involved in the inflammatory response, such as IL-6, IL-8, IL-12p40 and 
monocyte chemoattractant protein 1 (MCP-1), display a p38 dependent 
enrichment of histone H3 phosphorylation on SerlO in LPS stimulated myeloid 
cells. This phosphorylation enhances the accessibility of the cryptic NF-kB- 
binding sites marking promoters for increased NF-kB recruitment. Importantly, 
H3 phosphorylation is not carried out directly by p38, but more likely through 
MSK1 (Saccani et al., 2002). In addition, phosphorylation of histone H3 by the 
p38 pathway also contributes to the chromatin relaxation status necessary for 
nuclear excision repair factor assembly in response to UV-induced DNA lesions. 
Rapid activation of the p38 pathway in response to UV radiation helps to enhance 
the damaged-DNA-binding complex 2 (DDB2) ubiquitination, probably through
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DDB2 phosphorylation. Consequent DDB2 degradation facilitates the 
recruitment of xeroderma pigmentosum complementation group C (XPC) needed 
for continuation of the repair process (Zhao et al., 2008a).
In S. cerevisiae, the p38 homolog Hogl is recruited to the promoters of regulated 
genes through its association with transcription factors, which is important to 
stimulate RNA polymerase II as well as for recruitment of the Rpd3 histone 
deacetylase and SAGA (Spt-Ada-Gcn5-acetyltransferase) histone acetylase 
complexes, resulting in transcription initiation. Hogl also mediates the 
recruitment of the chromatin structure remodelling complex of the SWI/SNF 
family to osmoresponsive genes, which is required for the nucleosome 
rearrangements found in osmostress genes in response to high osmolarity (de and 
Posas, 2010). The importance of p38 signalling for the function of SWI/SNF 
chromatin remodellers has also been demonstrated in higher eukaryotes. Thus, 
during muscle differentiation, p38 is required for the association between 
myogenic differentiation factor D (MyoD) and the ATPase subunits of the 
SWI/SNF complex BRG and BRM. Moreover, the SWI/SNF subunit BRG1- 
associated factor 60 (BAF60) is phosphorylated by p38 in vitro, and the 
functional relevance of this phosphorylation has been established (Simone et al., 
2004). It is worth mentioning that several BAF60 isoforms have been implicated 
in the interactions between the SWI/SNF complex and transcription factors. In 
addition, BRG1 can interact with both MyoD and Pbx on the myogenin promoter 
(Lluis et al., 2006).
61
1.6.R Cellular localization
In contrast with other MAPKs, p38 alpha has no nuclear localization signal and 
has been detected in both the nucleus and the cytoplasm of non-stimulated cells. 
However, the subcellular localization upon activation is controversial. Some 
evidence indicates that, following activation, p38 alpha translocates from the 
cytoplasm to the nucleus (Raingeaud et al., 1995), but there is also evidence 
showing that, in response to specific stimuli, p38 alpha preferentially 
accumulates in the cytosol (Ben-Levy et al., 1998). The discrepancy could be due 
to the analysis of different pools of p38 alpha, as it is conceivable that p38 alpha 
molecules may be located in different subcellular compartments as well as bound 
to different partners. For example, the re-localization of activated p38 alpha to 
the cytoplasm has been ascribed to nuclear export in association with its substrate 
MK2. A recent study postulates that p38 alpha nuclear translocation could be 
relevant for the regulation of G2/M cell-cycle arrest and to promote DNA repair, 
since p38 alpha translocates to the nucleus upon activation by stimuli that induce 
DNA double-strand breaks, but not other stimuli (Wood et al., 2009). Such 
translocation does not require p38 alpha catalytic activity, but it is induced by a 
conformational change triggered by the phosphorylation on Thrl80 and Tyrl82 
at the activation loop (Wood et al., 2009). Since phosphorylation of p38alpha in 
response to DNA damage, but not in response to other stimuli, promotes nuclear 
accumulation, it is plausible that nuclear shuttling is also specifically induced by 
DNA damage. Therefore selective nuclear transport of p38alpha would require
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both its phosphorylation and active nuclear shuttling. Alternatively, DNA damage 
signals could release p38 alpha from docking molecules such as MK2 or TAB1 
that are known to retain p38 alpha in the cytosol (Engel et al., 1998; Lu et al., 
2006), perhaps due to conformational changes induced upon DNA damage.
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1.7: SIGNALING PATHWAY IN CANCER-SPECIFIC METABOLISM:
HIF-1 ALPHA REGULATION
Biological processes require inevitably availability of ATP produced by 
mitochondrial respiration and cytosolic glycolysis. In mammals, organisms and 
their cells modify energy supplies, substrates availability and metabolic demands 
by balancing the amount of ATP generated by the different systems of the cell. 
There are two major metabolic processes by which cells may obtain energy: 
lactic fermentation and aerobic respiration. In lactic fermentation, which occurs 
only in the cytosol, glucose is initially converted to pyruvate through glycolysis. 
Pyruvate is subsequently reduced to lactate, which is eliminated in the 
bloodstream. This process generates two ATPs per glucose molecule. In aerobic 
respiration glucose and other substrates are completely oxidized to carbon 
dioxide and water. It includes glycolysis, Krebs cycle and oxidative 
phosphorylation (OXPHOS), the last two processes occurring within 
mitochondria. Aerobic respiration is characterized by higher energy yield than 
lactic fermentation (ca. 15 times), but it can only occur in the presence of oxigen, 
which acts as electron acceptor, whereas fermentation can occur in its absence. 
Rapidly proliferating cells, key feature of embryogenesis, growth and 
tumorigenesis, exhibit a canonical anabolic profile, counterbalancing increased 
proliferative energy demands by exploiting the accelerated production of ATP by 
glycolysis (Chung et al., 2007). Cancer cells produce large amounts of lactate 
regardless of the availability of oxygen and for this reason their metabolism is
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often reported as “aerobic glycolysis.” This hypothesis, originally postulated by 
the Nobel Laureate Otto Warburg, came from the observation of a specific 
metabolic pattern in slices of living tissues. Thus, while in normal tissues lactate 
production occurs almost exclusively during oxygen absence, the so called 
Pasteur effect, this production is not eliminated in tumor slices by the presence of 
oxygen (WARBURG, 1956). Thus, he found that even in presence of oxygen, 
cancer cells prefer to metabolize glucose by glycolysis, respect to the more 
efficient oxidative phosphorylation. Glycolysis has the capacity to generate ATP 
at a higher rate than oxidative phosphorylation and so would be of advantage as 
long as glucose supplies are unlimited. Alternatively, it has been proposed that 
glycolytic metabolism arises as an adaptation to hypoxic conditions during the 
early phase of tumor development during which the vascularization is not 
complete, as it allows ATP production in the absence of oxygen (Gillies et al., 
2008). An important player in the stimulation of glucose consumption and 
production of lactate is the HIF-1, a heterodimer composed of the constitutively 
expressed HIF-1 beta and HIF-1 alpha subunit. HIF-1 alpha activation is highly 
associated with cancer cell growth and survival, tumor development, tumor 
angiogenesis, and poor clinical prognosis (Zhong et al., 1999; Bimer et al., 2000; 
Akakura et al., 2001; Kung et al., 2000). In histopathological studies, HIF-1 alpha 
expression has been detected in most primary tumors of the brain, breast, colon, 
lung, ovary, and prostate and their metastases but not in the corresponding 
normal tissues (Zhong et al., 1999). In brain tumors, HIF-1 alpha expression 
correlated with histological grade (Zagzag et al., 2000). The expression of EPO,
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another HIF-1 alpha targeted gene as well as the EPO receptor, is also markedly 
increased in gliomas and breast cancers (Acs et al., 2001). HIF-1 beta and HIF- 
1 alpha subunits (Wang et al., 1995) contain basic helix-loop-helix domains that 
mediate dimerization and DNA binding, as well as a second dimerization motif 
referred to as the PAS domain based upon its original identification in the PER, 
ARNT, and SIM proteins. A superfamily of PAS domain proteins has been 
identified, the majority of which are prokaryotic signal transduction molecules 
involved in responding to environmental stimuli such as light, oxigen 
concentration, and redox state (Taylor and Zhulin, 1999). This finding suggested 
that HIF-1 alpha might be directly regulated by oxigen because the PAS domains 
of several prokaryotic proteins bind prosthetic groups such as heme. This 
complex is rapidly stabilized in absence of oxygen (Huang et al., 1998). HIF-1 
alpha is expressed under the control of growth-factor signaling, in particular the 
PI3K/AKT/mTOR pathway (Cramer et al., 2003; Jiang et al., 2001). While cells 
are in normoxic conditions, HIF-1 alpha goes through a posttranslational 
modification by prolyl hydroxylation, In well oxygenated cells (normoxia), the 
hydroxylation of two proline residues (P402 and P564 in human HIF-1 alpha) by 
the HIF-prolyl hydroxylases [prolyl hydroxylases domains (PHDs)] allows the 
specific recognition and polyubiquitination by the von Hippel-Lindau protein 
(pVHL) E3-ligase complex, leading to proteasomal degradation (Maxwell et al.,
1999) (Figure 6). Moreover, the hydroxylation of an asparagine residue (N803 in 
human HIF-1 alpha) by the factor inhibiting HIF (FIH) prevents binding of the
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Figure 6. Structure and critical aminoacids of HIF-1 alpha. In this picture 
taken from (Kizaka-Kondoh et al., 2009) are indicated the domains of HIF-1 
alpha (bHLH, PAS and ODDD) and its aminoacids targeted for regulation, such 
as the prolin P402 and P564 and asparagine N803.
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coactivator p300/CBP and hence blocks HIF-1 alpha transcriptional activity 
(Lando et al., 2002) (Figure 6). In contrast, restricted availability of oxygen, by 
relaxing HIF-1 alpha hydroxylation, results in HIF-1 alpha stabilization and 
activation of the HIF transcriptional complex. Like FIH, the PHDs belong to the 
super family of iron- and 2-oxoglutarate-dependent dioxygenases, which, by 
using oxigen as a cosubstrate, provide the molecular basis for their oxigen- 
sensing function (Berra et al., 2006). In mammalian cells, three PHDs isoforms 
have been identified (PHD1, PHD2, and PHD3) and shown to hydroxylate HIF-1 
alpha in cellulo depending on their relative abundance (Appelhoff et al., 2004). 
PHD2 has a dominant role, as it is the rate-limiting enzyme that sets the low 
steady-state level of HIF-1 alpha in normoxia (Berra et al., 2003). Constitutive 
cellular stabilization of HIF-1 alpha during normoxia is possible only in presence 
of mutations in the tumor suppressor VHL that occur in tumors. VHL disease is a 
hereditary cancer syndrome characterized by the development of highly vascular 
tumors that overproduce hypoxia-inducible mRNAs such as VEGF (Ivan and 
Kaelin, Jr., 2001). The product of the VHL tumor suppressor gene, pVHL, is a 
component of a multiprotein complex that bears structural and functional 
similarity to SCF (Skpl/ Cdc53 or Cullin/F-box) ubiquitin ligases (Stebbins et al., 
1999; Ohh et al., 2000; Deshaies, 1999). In the presence of oxygen, pVHL, in 
association with elongin B and elongin C, binds directly to HIF-1 alpha subunits 
and targets them for polyubiquitination and destruction (Ohh et al., 2000; 
Tanimoto et al., 2000). Cells lacking functional pVHL cannot degrade HIF-1 
alpha and thus overproduce mRNAs encoded by HIF target genes (Maxwell et
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al., 1999). pVHL binds to a region of HIF-1 alpha called the oxygen-dependent 
degradation domain (ODDD) (Ohh et al., 2000), driving HIF-1 alpha toward 
ubiquitination and degradation. Dimethyloxalylglycine (DMOG), which is a 
competitive antagonist of alpha-ketoglutarate, inhibits hydroxylases and induces 
HIF-1-dependent transcription (Epstein et al., 2001). HIF-1 alpha activity is also 
induced by iron chelators, e.g., desferrioxamine (DFO) and cobalt chloride, 
which inhibit hydroxylases by displacing Fe(II) from the catalytic center (Epstein 
et al., 2001). During hypoxia, prolylhydroxylation is prevented by reactive 
oxygen species (ROS) generated in the mitochondria, stabilizing HIF-1 alpha 
accumulation in the nucleus where it forms a complex with the constitutively 
expressed HIF-1 beta favoring the recruiment of transcriptional coactivator 
proteins, such as p300/CBP, and bind to the hypoxia response elements present in 
>70 known genes, enhanching their transcription (Brunelle et al., 2005; 
Mansfield et al., 2005; Guzy et al., 2005). HIF-1 alpha induces genes that control 
crucial features of cancer biology, embracing angiogenesis, glucose metabolism, 
cell proliferation and invasion. Under hypoxic conditions, HIF-1 alpha mediates a 
transition from oxidative to glycolytic metabolism through its regulation of four 
factors: pyruvate dehydrogenase (PDH) kinase 1 (PDK1), lactate dehydrogenase 
A (LDHa), BNIP3, and BNIP3L. PDK1 inhibits the conversion of pyruvate to 
acetyl coenzyme A for entry into the tricarboxylic acid cycle (Kim et al., 2006; 
Papandreou et al., 2006). LDHa converts pyruvate to lactate (Semenza et al., 
1996). Finally, BNIP3 (Zhang et al., 2008) and BNIP3L (Bellot et al., 2009) 
mediate selective mitochondrial autophagy. HIF-1 alpha also mediates a subunit
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switch in cytochrome c oxidase (COX) that improves the efficiency of electron 
transfer under hypoxic conditions (Fukuda et al., 2007). HIF-1 alpha does not 
only stimulate glycolysis in tumor cells. Indeed, it has been shown that it is able 
to suppress the respiratory activity of mitochondria, suggesting that it can act as a 
master switch between glycolysis and oxidative phosphorylation (Kim et al., 
2006).
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1.8: METABOLIC EFFECTORS MEET CHROMATIN: THE F0X03A
FAMILY
In molecular biology and genetics, a transcription factor is a protein that binds to 
specific DNA sequences, thereby controlling the transcription of genetic 
information from DNA to mRNA (Karin, 1990; Latchman, 1993). Transcription 
factors perform this function alone or with other proteins in a complex, by 
promoting (as an activator), or blocking (as a repressor) the recruitment of RNA 
polymerase to specific genes (Roeder, 1996; Nikolov and Burley, 1997; Lee and 
Young, 2000).
A defining feature of transcription factors is that they contain one or more DNA- 
binding domains (DBDs), which attach to specific sequences of DNA adjacent to 
the genes that they regulate (Mitchell and Tjian, 1989; Ptashne and Gann, 1997). 
Additional proteins such as coactivators, chromatin remodelers, histone 
acetylases, deacetylases, kinases, and methylases, while also playing crucial roles 
in gene regulation, lack DNA-binding domains, and, therefore, are not classified 
as transcription factors (Brivanlou and Darnell, Jr., 2002). A class of transcription 
factors possesses a particular DBD, the "forkhead domain", called in this way 
after the isolation of the first member. This "forkhead domain" is an approximate 
100-amino acid, monomeric DBD and represents a variant o f the helix-tum-helix 
motif. It is made up of three helices and two characteristic large loops or 
butterfly-like ‘wings’. The high degree of sequence homology within the DBD is 
in contrast with an almost complete lack of similarity in the N-terminal and C-
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terminal transactivation domains. Over the last decade, more than 100 members 
have been identified, with roles in development, differentiation, proliferation, 
apoptosis, stress resistance and metabolism (Carlsson and Mahlapuu, 2002) 
(Figure 7). During evolution, the number of forkhead genes appears to have 
increased, with greater numbers identified in vertebrates than in invertebrates; the 
human forkhead-box gene family consists of at least 43 members. Several years 
ago, a standard nomenclature for this family of proteins was introduced 
(Kaestner et al., 2000), and Fox (Forkhead box) was adopted as a unified symbol 
for all chordate forkhead/winged helix transcription factors. Subclasses are 
designated by a letter, and within each subclass proteins are given a number.
The FoxO class of transcription factors consists of four members: FoxOl, 3 A, 4 
and 6. The alternative names for these genes used in earlier studies were FKHR 
CFoxOl), FKHRL1 {FoxO3A) and AFX  or Mllt7 (Fox04). Fox02, originally 
named AF6q21 and cloned as a novel fusion partner for the AF6 protein, is 
homologous to Fox03a and likely not a separate FoxO. Fox05 is expressed in 
Danio rerio only. FoxOl, 3A and 4 are ubiquitously expressed, but between 
different cell types or organs, the expression level of these FoxOs can differ 
considerably. For example, FoxOl is highly expressed in adipose tissue, whereas 
Fox04 is highly expressed in muscle and Fox03A in liver (Furuyama et al.,
2000). Fox06 expression appears restricted to brain (Jacobs et al., 2003). Splice 
variants have been described for FoxOl, 3A and 4 (Yang et al., 2002). Because of 
the shared DBD, FoxOs are expected to bind to similar sequences within the
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Figure 7. Transcriptional outputs of FoxO familyactivity. Increased class O 
forkhead box transcription factor (FoxO) activity participates in several cellular 
processes, such as inhibition of the cell cycle, regulation of cell death, protection 
from cellular (oxidative) stress, by the upregulation of catalase and regulation of 
cellular metabolism (gluconeogenesis and fatty-acid oxidation) trough 
phosphoenolpyruvate carboxykinase (PEPCK). The picture is taken from (van 
der Horst and Burgering, 2007).
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DNA and a core consensus DNA sequence for FoxO binding has been 
determined (5TTGTTTAC3') (Furuyama et al., 2000). However, the details of 
DNA binding of the FoxOs are still elusive.
Initial interest in the FoxO transcription factors stemmed from the fact that they 
were identified as translocation partners in a number of cancers. The best studied 
example being the t(2;13) and t(l;13) translocations present in a percentage of 
alveolar rhabdomyosarcomas resulting in a PAX3-F0X01 (Galili et al., 1993) 
and PAX7-F0X01 (Davis et al., 1994) fusion protein, respectively. Although 
these observations did not directly imply a role for FoxOs in tumorigenesis, it has 
become clear by now that FoxOs are genuine tumor-suppressors. An evolutionary 
conserved feature of FoxO transcription factors is that they function as 
downstream effectors of the PI3K/AKT (Burgering and Kops, 2002). The 
PI3K/AKT signalling cascade is a key pathway by which cells may respond to a 
wide range of stimuli, which may be generated intrinsically (for example, growth 
factors, cytokines and cell-cell contact) or from an external source (for example, 
irradiation, and physical or genotoxic stress) (Leevers et al., 1999; Hennessy et 
al., 2005; Wymann and Marone, 2005; Samuels and Ericson, 2006). At the 
molecular level, many of the PI3K/AKT-mediated mitogenic responses are 
achieved through the direct repression of FoxO transcription factors by AKT- 
mediated phosphorylation, promoting nuclear export, proteosomal degradation 
and a decrease in transactivation activity (Brunet et al., 1999; Brunet et al., 2001; 
Kops et al., 2002b; Jacobs et al., 2003). Oxidative stress induces translocation of 
FoxO from the cytosol to the nucleus (Henderson and Johnson, 2001; Brunet et
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al., 2004; Essers et al., 2004) and peroxide-activated JNK phosphorylates Fox04 
at sites that are important for Fox04 activity (Essers et al., 2004). AKT-mediated 
phosphorylation of FoxO induces binding of 14-3-3 proteins and this correlates 
with inhibition of FoxO through nuclear exclusion. JNK has been shown to 
phosphorylate 14-3-3, which results in reduced 14-3-3 binding to partner proteins 
(Sunayama et al., 2005). Another important factor in the activation of FOXO 
family members is the energy sensor AMP-activated Protein Kinase (AMPK). 
AMPK directly phosphorylates human FOX03 at six previously unidentified 
residues in vitro (Greer et al., 2007). AMPK is necessary and sufficient for the 
phosphorylation of Fox03A at these sites in cells. Mutation in these 
phosphorilation sites impairs Fox03 A-dependent transcription but does not affect 
Fox03 A localization. A genome-wide microarray analysis indicates that mutation 
of AMPK phosphorylation sites in Fox03 A specifically impairs the expression of 
a subset of target genes, including oxidative stress resistance and energy 
metabolism genes (Greer et al., 2007). Recently, we demonstrated that the 
activity of AMPK is necessary for Fox03 A-dependent transcription (Chiacchiera 
et al., 2009).
Cell cycle checkpoints are activated in response to genotoxic stress induced by 
most chemotherapeutic drugs (Lukas et al., 2004; Bartkova et al., 2005). Thus, in 
addition to preceding differentiation, cell cycle arrest may also be induced by 
genotoxic stress and lead to apoptosis. Indeed, most chemotherapeutic drugs are 
reported to arrest or delay cell cycle progression, and if the DNA damage or other
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cellular defects are extensive, the cell will undergo either apoptosis or cellular 
senescence (Lukas et al., 2004; Bartkova et al., 2005).
Moreover, cancer cells may be considered to display an enhanced or higher level 
of basal stress, such as increased levels of ROS or stress kinase activity, and it is 
precisely the deregulation of cell cycle checkpoints that allow cancer cells to 
tolerate such cellular conditions, while simultaneously promoting genomic 
instability and tumor progression (Giles, 2006; Wu, 2006; Fruehauf and 
Meyskens, Jr., 2007). One such mechanism by which cancer cells can tolerate 
cellular stress is the deactivation of Fox03 A, which would be anticipated to be 
activated by oxidative stress and stress kinases, both of which may converge 
through JNK-mediated phosphorylation of Fox03A (Essers et al., 2005; Essers et 
al., 2004; Vogt et al., 2005; Huang and Tindall, 2007). Thus, it is not perhaps 
surprising that the re-introduction of Fox03A can induce tumor cell kill in cancer 
cells that have repressed Fox03A activity (Modur et al., 2002), and also that 
activation of FoxO transcription factors has a role in mediating the cytostatic and 
cytotoxic functions of chemotherapeutic drugs in some cancer types. However, 
the cell cycle arrest induced by FoxO can have an influence on the eventual 
outcome in terms of cell fate and may also promote DNA damage repair and 
stress resistance (Tran et al., 2002). FoxO family members have also been shown 
to promote mammalian cell survival by inducing cell cycle arrest and quiescence 
in response to oxidative stress (Brunet et al., 2004; Kops et al., 2002a; Essers et 
al., 2004; Medema et al., 2000). At the same time, the CDKI p27Kipl, the 
prominent downstream target of FoxO, which blocks progression of cells from
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late G1 to S phase, has also been implicated directly in the induction of apoptosis 
by FoxO (Wang et al., 1997; Wu et al., 1999; Dijkers et al., 2000).
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Chapter 2: MATERIAL AND METHODS
2.1 Cell Culture
HT29, HCT116, OVCAR-3, A2780, SKOV-3 and DU145 cells were maintained 
in DMEM while LS174T and PC3 in RPMI 1640, each supplemented with 10% 
FBS, penicillin, and streptomycin, avoiding confluence at any time. All the cell 
lines were purchased from ATCC.
2.2 Reagents
SB202190 (SB; 10 mM stock) , Propidium Iodide (P.I.), trypan blue, Compound 
C (CC; 10 mM stock), AICAR (50mM stock), Deferoxamine (DFO; 100 mM 
stock), Cisplatin (CDDP; 30 mM stock) were purchased from Sigma. Z-IEDT- 
FMK from BD Bioscience. Dimethyl sulfoxide (DMSO) was purchased from 
SIGMA.
2.3 Microscopic Quantization of Viability, Cell Death, and Autophagic Cells
The viability and cell death of the reported cell lines were scored by cell 
counting. Briefly, at the indicated time points, the supernatants (containing 
dead/floating cells) were collected, and the remaining adherent cells were 
detached with Trypsin/EDTA (Sigma). Then, both cell suspensions were mixed 
and centrifuged. Cell pellets were suspended in 1M phosphate-buffered saline 
(PBS), and 10 pi were mixed with an equal volume of 0.01% trypan blue 
solution. The mixture was then transferred to the hemacytometer. Viable cells
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(unstained cells) and dead cells (stained cells) were counted with a phase contrast 
microscope (x40). The percentage of viable cells (V) (% = 100 x V / [V + D]) 
and the percentage of dead cells (D) (% = 1 0 0 x D / [ V  + D]) were determined. 
The percentage of autophagic cells was measured by optical microscopy by 
measuring the number of vacuolated cells (A) against the total number of cells (% 
= 100 x A / [NA + A], where NA means "non autophagic". The data shown in 
Results are representative of three or more independent sets of experiments.
2.4 Proliferation Assay
Proliferation assays were performed using the colorimetric WST-1 assay 
(Roche). Briefly, 2x103 cells for each cell line were cultured in 96-well plate in 
the presence or the absence of SB for up to 72 hours (OvCa cells experiments), 
96 hours (PCa cells experiments) or 144 hours (CRC cells experiments). In the 
case of CDDP experiment CRC cells were treated also with CDDP alone or in 
combination with SB. In each experiment, DMSO was used as a vehicle. At the 
indicated time points, the WST-1 reagent was added with a final dilution of 1/10 
for 30 minutes. The plate was shaken thoroughly for 60 seconds on a shaker, and 
then the absorbance of the samples was measured against a background control 
using a spectrophotometer at 450 nm, the reference wavelength being 650 nm. 
Each experiment was performed three times.
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2.R Colony Formation Assay
CRC, OvCa and PCa cells were cultured in 60-mm dishes in the presence or the 
absence of SB and/or CDDP (CDDP experiment). After 72 hours, the medium 
was discarded and the cells were washed 2 times with IX phosphate-buffered 
saline. Two milliliters of Coomassie brilliant blue (Bradford) dye were added in 
each dish for 5 minutes. The cells were then washed with 70% ethanol to remove 
the excess of dye. The plates were dried at room temperature.
2.6 Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted with TRI reagent (Sigma) following the manufacturer’s 
instructions. The samples were then treated with DNAase-1 (Ambion). 1 to 4 pg 
of total RNA were retrotranscribed using the High-Capacity DNA Archive Kit 
(Applied Biosystem) following the manufacturer’s instructions. Polymerase chain 
reactions (PCRs) were performed in triplicate using the ABI 7500HT machine 
(Applied Biosystem). For all experiments, the following PCR conditions were 
used: 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds, 60°C 
for 60 seconds, and 72°C for 45 seconds. The quantitative normalization of the 
cDNA in each sample was performed using glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and beta-actin amplifications as internal control. 
Relative quantification was done using the AACT method. Each experiment were 
repeated three times. Each sample was loaded on the real time plate in duplicate.
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2.7 Multiplex Real-Time PCR
Multiplex real-time PCRs (RT-PCRs) were performed with 5-U/ pi Taq DNA 
polymerase, 25 mmol/L MgC12, lOx Taq buffer, and 10 mmol/L 
deoxyribonucleotide triphosphates (dNTP) purchased from 5PRIME. The 
following PCR conditions were used: 95°C for 15 minutes, followed by 28 cycles 
at 94°C for 30 seconds, 59°C for 90 seconds, 72°C for 60 seconds, and in the 
final step, 72°C for 10 minutes. The samples were loaded on a 2% agarose gel 
and pictures were taken.
2.8 Immunoblot analysis
Immunoblots were performed according to the instructions of Cell Signaling 
Technology, Inc. Briefly, cells were homogenized in IX lysis buffer (50 mmol/L 
Tris-HCl, pH 7.4; 5 mmol/L EDTA; 250 mmol/L NaCl; 0.1% Triton X- 100) 
supplemented with protease and phosphatase inhibitors (1 mmol/L 
phenylmethanesulphonylfluoride (PMSF), 1.5 mmol/L pepstatin A, 2 mmol/L 
leupeptin, 10 pg/mL aprotinin, 5 mmol/L NaF, and 1 mmol/L Na3V04). From 20 
to 40 pg of protein extracts from each sample were denatured in 5X Laemmli 
sample buffer and used for Western blot analysis. Western blots were executed 
using antibodies directed against alpha-actin (Sigma), pospho AKT (Ser473), 
AKT, phospho AMPK (Thrl72), AMPK, p38 alpha, p38 total, phospho p38, 
hexokinase 2 (HK2; all from Cell Signaling Technology, Inc), Fox03A total, 
phospho Fox03A (Thr32; Santa Cruz Biotechnology), HIF-1 alpha (Abeam), 
activated caspase 3-8, PARP-1 cleaved fragment (p85), MAP1LC3 (LC3), PTEN,
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phospho MK2, LKB1, phospho ACC. Western blots were developed with the 
ECL Plus chemiluminescence reagent (GE Healthcare) as per manufacturer’s 
instructions. The densitometric evaluation was performed by the ImageJ 
software.
2.9 Immunofluorescence assay
CRC cells were seeded on glass coverslips and treated for 48 hours with SB, 
CDDP alone or in combination. At the end of the treatment cells were fixed in 
4% paraformaldehyde and permeabilized using 0.1% Triton X-100. Coverslips 
were incubated with the indicated primary antibodies. Secondary antibodies were 
Alexa Fluor 488 and Alexa Fluor 594 from Invitrogen; nuclei were 
counterstained using P.I. Slides were sealed using Vectashield mounting medium 
(Vector Laboratories). Images were acquired using a Zeiss LSM-5 Pascal 
confocal microscopy.
2.10 ATP assay
HT29 cells were treated with SB or DMSO, as control, for up 8 hours. At the 
indicated time, Cells were collected, counted and lysed and ATP levels were 
determined by luciferine-luciferase assay; using the ATP Bioluminescence Assay 
kit (Roche) according to standard protocol. The results were normalized to the 
number of cells. The experiment were done five times.
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2.11 FACS analysis
HT29 cells and HCT116 cells were plated and treated as indicated in the text. At 
the indicated time point cells were collected and counted to obtain the same 
number of cells, the samples were wash with PBS lx  two times risospende with 
IX Binding Buffer (Sigma). 5pi of Annexin V FITC conjugate (Sigma) and 10pl 
of P.I. were added and incubate for 10 minutes. 20 thousands of events were 
counted by a BD FACS Advantage (BD Bioscience)
2.12 RNA interference
CRC cells were seeded in a 30-mm dish and transfected with 100 nM siRNA 
using RNAi MAX (Invitrogen) following manufacturer’s instructions. siRNA 
against Fox03A was added to HT29 cells and HCT116 cells for 12 hours. Then 
medium was replaced with fresh one. After 36 hours the cells were treated with 
CDDP alone (HCT116 cells) or SB plus CDDP (HT29 cells) for further 48 hours. 
Immunoblotting of cell lysate was performed to evaluate the protein levels of 
Fox03A, p85 and actin. A scramble siRNA (Invitrogen) was used as control.
2.13 Glucose and Lactate assay
HT29 cells were plated in complete medium and treated or not with SB. At the 
indicated time points 50pl for each sample were mixed with 50pl of Glucose 
Reaction Mix (BioVision Research Products). After 30 minutes of incubation at 
37°, protected from the light, the O.D at 570 nm was measured using a microplate 
reader. The concentration of glucose was estimated using a standard curve and
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normalized on cell number. For lactate assay HT29 cells were treated as 
previously described. At the indicated time points 50pl of medium was mixed 
with 50pl of Lactate Reaction Mix (BioVision Research Product). After 30 
minute at room temperature the O.D. at 450nm was measured using a microplate 
reader. The amount of lactate in the medium was estimated using a standard 
curve and normalized on cell number. Each experiment was performed three 
times and samples were plated in duplicate.
2.14. Statistical analysis.
All results are expressed as mean ± SEM. Gene expression statistical analysis 
were performed using NCSS statistical and power analysis software 2007. 
Multiple groups were tested by one-way ANOVA or two ways ANOVA repeated 
measures where appropriate, followed by Fisher’s least significant difference test 
for unpaired data. Comparisons of two groups were performed using a Student’s t 
test followed by Mann-Whitney U test where appropriate. A P < 0.05 was 
considered significant.
2.1R. CONFAC software
The conserved transcription factor binding site (CONFAC) software enables the 
high-throughput identification of conserved transcription factor binding sites 
(TFBSs) in the regulatory regions of hundreds of genes at a time. The CONFAC 
software compares non-coding regulatory sequences between human and mouse 
genomes to enable identification of conserved TFBSs that are significantly
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enriched in promoters of gene clusters from microarray analyses compared to sets 
of unchanging control genes using a Mann-Whitney Latest. For analysis go to 
http://morenolab.whitehead.emory.edu/cgi-bin/confac/login.pl (Karanam and 
Moreno, 2004)
2.16. Densitometry
Densitometry evaluation of western blotting were performed using Photoshop 
software (Adobe). Briefly, rectangular section of the same area of the 
immunoblot bands were created. For each band was analyzed the mean value 
obtained from the command "Histogram" (a). To avoid overestimation, for each 
band is subtracted the mean of the same rectangular section taken from a zone 
right above the band (b). The subtraction a-b gives the "normalized" value (c). 
This operation was done for each band, included the untreated one. Finally, each 
c is divided by the c of control (cc). The ratio of the untreated was 1.
Example:
band 1 (control): a=150, b= 30, cc=(a-b)= 150-30=120; 
band 2 (compound X): a=120, b= 60; cx=(a-b)= 120-60=60 
Result:
Cc/cc= 1; cx/cc= 60/120= 0,5.
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Chapter 3: BACKGROUND
Since the beginning of my undergraduate studies, I worked with Dr. Simone and 
colleagues to elucidate the role of p38 alpha in CRC homeostasis, in which we 
demonstrated that the inhibition of this kinase led to the induction of autophagy, 
cell cycle arrest and cell death with autophagic features. Indeed, we induced 
pharmacological blockade of the p38 cascade using SB and analyzed the gene 
expression profile of HT29 cells growing logarithmically, confluent in culture or 
induced to differentiate. Five genes were first considered, three of them being cell 
cycle-related: cyclin E, cyclin A and p21. The other two genes codify for tissue- 
specific proteins: sucrose isomaltase (SI) and villin. At the onset of 
differentiation, SB treatment inhibits the expression of p21, SI and villin 
confirming the role of the p38 pathway in the differentiation program of distinct 
cell types (Comes et al., 2007). Surprisingly, we discovered that p38 alpha is 
required for CRC cell proliferation and survival as pharmacological blockade or 
genetic depletion (by RNAi) of its kinase activity induced growth arrest, 
autophagy and cell death in a cell type-specific manner (Comes et al., 2007). Of 
note, p38 alpha blockade in HT29 cells induced the formation of large 
cytoplasmic vacuoles regardless of culture conditions (Comes et al., 2007). To 
investigate the nature of these vacuoles, we employed different cytological 
methods such as periodic-acid Schiff (PAS), Papanicolaou, Sudan black B and 
Oil red O. Among them only PAS demonstrated a dot-like staining within 
vacuoles suggesting the presence of glycoproteins (Comes et al., 2007).
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Numerous large vacuoles filled up with dense material, autophagic vacuoles 
containing cell organelle debris and double-membrane autophagosomes were 
recognized by Transmission Electron Microscopy (TEM). The detection of these 
structures, termed as the ‘golden standard’ for assessing autophagic activity, 
clearly indicated that pharmacological blockade of p38 alpha induced an 
autophagic response in HT29 cells (Comes et al., 2007). To better characterize 
this process, we evaluated the expression of the GABARAP gene, one of the 
human homologs of the yeast ATG8 gene. ATG8 is a member of a novel 
ubiquitin-like protein family and an essential component of the autophagic 
machinery. In yeast, it is upregulated by rapamycin-dependent Tor inhibition and 
nitrogen starvation. In HT29 cells, GABARAP expression levels were 
significantly augmented by p38 alpha blockade and correlated with autophagic 
vacuoles and autophagosomes. Notably, pharmacological blockade of SB- 
dependent autophagy by 3-methyladenine (3MA), a specific inhibitor of 
autophagy, not only failed to increase viability, but even increased cell death by 
inducing a switch from autophagic cell death to apoptosis (Comes et al., 2007). 
To get further insight into the involvement of p38 alpha in the autophagic 
response, we extended our investigation to other 4 human CRC cell lines: 
CAC02, SW480, LS174T and HCT116. Cytological and morphological 
evaluation confirmed the SB-mediated induction of growth arrest and autophagic 
cell death in all CRC lines. Consistently, SB-mediated upregulation of 
GABARAP was detected in all cell lines tested (Comes et al., 2007). To 
investigate whether p38 alpha inhibition induced PCD type II in a cell type-
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specific manner, Hep3B liver carcinoma cells, HeLa cervical carcinoma cells, 
HEK293 embryonic kidney cells, and human fetal skin fibroblasts (hFSF) were 
exposed to SB for 24 hours. Pharmacological inhibition of p38 alpha failed to 
induce cell cycle arrest, autophagy or cell death, nor did it promote GABARAP 
upregulation in any of the cell lines tested (Comes et al., 2007).
Furthermore, my colleagues demonstrated that SB treatment is protective upon 
tumor development in a mouse model of CRC xenograft. They injected 5x106 
LS174T cells into each flank of athymic nude mice. Once the tumors reached a 
measurable volume (mean = 61.6 mm3), p38 alpha was continuously inhibited by 
daily intraperitoneal injection of SB. After 10 days mice were sacrificed since 
control tumors attained a mean volume of 500 mm . We found that SB treatment 
can inhibit tumor growth in nude mice in a dose-dependent manner. To further 
investigate the efect of p38 alpha inhibition in vivo, we used the murine model of 
colorectal cancer (APCmin/+ ) and , once induced the tumor formation, we treated 
these mice with SB for two weeks. This experiment showed that SB treatment in 
this model induced a strong reduction both of the volume and of the number of 
tumors. It is worth noting that no signs of liver damage were detected in mice 
serum (Chiacchiera et al.,2009).
In conclusion, the inhibition of p38 alpha in CRCs provoked the induction of cell 
growth arrest, the activation of autophagy and cell death with autophagic features 
(Comes et al., 2007). Moreover, the inactivation of the p38 alpha greatly affected 
the cell growth of xenografts and induced a strong reduction in tumor volume and 
number in in vivo experiments (Chiacchiera et al., 2009).
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3.1 AIM OF STUDY
As discussed before, the pharmacological inhibition of p38 alpha with SB and its 
genetic ablation induced autophagy, cell cycle arrest and cell death with 
autophagic features in CRC cells (Comes et al., 2007). Moreover, this inhibition 
increased the mRNA levels of different metabolic genes (Chiacchiera et al., 
2009).
Since autophagy is activated by energy demand, due to the high levels of 
intracellular AMP (Hardie, 2011) and, recently, p38 alpha was associated to the 
inhibition of autophagy, by the sequestering of protein involved in 
autophagosomes formation (Webber and Tooze, 2010), the aim of my studies was 
to understand the possible causes of this autophagic activation during the 
pharmacological inhibition of p38 alpha and the putative role of this protein in 
this scenario.
To this purpose we used three CRC cell lines, HT29, HCT116 and LS174T and 
we focused our attention on the glycolytic pathway, since it is the fastest way to 
obtain energy by cancer cells (Warburg, 1956). Then we extend our analysis to 
other malignancies, such as OvCa and PCa, evaluating whether the inhibition of 
p38 alpha could be useful also for other types of cancer. However, we checked 
whether there were implied other regulator proteins and whether the inhibition of 
p38 alpha could modify other pathways different from autophagy. Moreover, this 
kinase is linked also with the resistance to chemotherapeutics, such as CPT-11 
and 5-FU (Paillas et al.,2011; Yang et al.,2011) and its inhibition or genetic
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ablation was linked to the overcome of the resistance to these compounds. We 
also decided to evaluate the role of p38 alpha in the treatment with CDDP of two 
CRC cell lines, HCT116 and HT29, which showed two different outcomes to this 
treatment. The inhibition of p38 alpha in this scenario could be useful to 
understand the mechanisms related to the resistance to CDDP in CRC cell lines
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Chapter 4: RESULTS
4.1 p38 alpha inhibition in colorectal cancer
One of the effect of p38 alpha inhibition in CRC is the activation of autophagic 
pathway (Conies et al., 2007). This pathway is activated by energy demand 
(Hardie, 2011) so we measured the intracellular levels of ATP during p38 alpha 
inhibition. We cultured HT29 cells for up to 8 hours in the presence of SB or 
DMSO, used as a control. Then, we measured the amounts of ATP with a 
luciferin-luciferase assay (Figure 8). The results showed a decrease in the levels 
of ATP in the first hours of treatment in SB-treated cells.
Since cancer cells predominantly produce ATP by constitutively activated 
aerobic glycolisys (WARBURG, 1956; Christofk et al., 2008), we determined 
whether this decrease could be attributed to variations in this pathway. To support 
the hypothesis that p38 alpha inhibition could produce a variation in glycolytic 
pathway, we treated HT29 cells with SB or DMSO for up two hours and we 
measured by real time PCR the levels of mRNA of the most important genes 
involved in glycolysis such as glucose transporter 1 (GLUT1), the rate-limiting 
enzymes HK1 and HK2, pyruvate kinase isoform M2 (PKM2), and LDHa. 
Moreover, it has been shown that tumor cells express exclusively the PKM2, 
which is necessary for aerobic glycolysis, and that provides a selective growth 
advantage for tumor cells in vivo (Christofk et al., 2008). It is worth noting that 
knockdown of LDHa has been proven to severely diminish tumorigenicity of
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Figure 8. Effect of SB treatment on ATP levels in HT29 cell line. HT29 were 
cultured with or without IOjiM of SB for 8 hours and intracellular ATP levels 
were measured by luciferin-luciferase assay. ATP levels reduced in the first hours 
of SB treatment and then increased probably due the activation of autophagy. 
ATP levels of DMSO treated cells were used as control. Results are expressed as 
mean ±SEM (n=5). Comparison between ATP levels of SB-treated and DMSO 
treated cells was performed using a student’s t test followed by Mann-Witney U 
test (*=/K0.05).
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Figure 9. Evaluation of p38 alpha inhibition on Glycolytic pathway. HT29 
cells were treated with SB (10pM) or DMSO for up to 2 hours. A) mRNA levels 
of PKM2, LDHa, HK1, HK2 and GLUT1 were analyzed by real-time PCR at the 
indicated time points. All these genes decrease in a time dependent manner, 
indicating that glycolytic genes expression is affected by p38 alpha blockade, 
beta-actin was used as calibrator of mRNA quantity. The relative mRNA levels 
are expressed as fold induction. Results are expressed as mean ±SEM (n=3). B) 
Glucose consumption was measured as the difference of glucose amount in the 
medium of HT29 cells SB-treated versus DMSO-treated at the indicated time 
points. The consumption of glucose by SB-treated cells was lower than DMSO- 
treated cells. The measures were normalized on cells number. Results are 
expressed as mean ±SEM (n=3). Comparison of glucose amount in the medium 
between SB-treated and DMSO treated cells was performed using a student’s t 
test followed by Mann-Witney U test (*=p<0.05). Lactate production was 
measured comparing lactate amount in the medium of SB-treated and DMSO- 
treated cells at the indicated time points. The amount of lactate in the medium of 
SB-treated cells decreased in a time dependent manner. The measures were 
normalized on cells number. Results are expressed as mean ±SEM (n=3). 
Comparison of glucose amount in the medium between SB-treated and DMSO 
treated cells was performed using a student’s t test followed by Mann-Witney U 
test (*=p<0.05).
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cancer cells in mice (Fantin et al., 2006) (Figure 9A). As shown in the figure, 
these genes resulted downregulated in SB-treated cells, especially GLUT1 and 
HK2, which are the transporter of glucose in to the cells and first enzime in its 
metabolism. To have a wider view in the glucose metabolism, we treated HT29 
cells with SB for up to two hours and we quantified the levels of extracellular 
glucose and the lactate amount in the medium, using a colorimetric assay (Figure 
9B,C). Both the glucose consumption and the lactate extrusion decreased during 
the use of SB in this cell line. These results indicate that p38 alpha inhibition 
could trigger a modification of the glucose metabolism. To better evaluate the 
glycolytic pathway, we treated HT29 cells and LS154T cells with SB for up to 72 
hours and we performed a real time PCR to evaluate the expression levels of 
genes involved in this pathway (Figure 10). Worthy of note, among the genes 
used for our analysis only HK1 was not downregulated, probably because is not 
the main isoform used by CRC cell lines to metabolize the glucose, while the 
other genes were rapidly downregulated and mainteined at a decreased 
expression levels for longer time during p38 alpha inhibition. Given the fact that 
all these genes are HIF-1 alpha targets genes (Schofield and Ratcliffe, 2004), we 
decided to investigate whether a relationship could exist between p38 alpha and 
this transcription factor. We treated HT29 cells and LS174T cells with SB for up 
to 96 hours and we carried out a western blot analysis, to detect the protein levels 
of HIF-1 alpha (Figure 11 A). As shown in the figure, in both cell lines HIF-1 
alpha protein levels decreased in a time dependent manner. To confirm these
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Figure 10. Effect of SB treatment on Glycolytic genes expression. HT29 cells 
and LS174T cells were treated for up to 72 hours with SB (lOpM). The glycolytic 
genes (GLUT1, HK1/2, PKM2 and LHDa) were analyzed by real time PCR. The 
prolonged p38 alpha inhibition affected the transcription of these genes in both 
cell lines, indicating that this kinase could sustain glycolytic pathway. The 
relative mRNA levels are expressed as fold induction, beta-actin was used as 
calibrator of mRNA quantity. The relative mRNA levels are expressed as fold 
induction. Results are expressed as mean ±SEM (n=3).
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Figure 11. Relationship between SB-treatment and HIF-1 alpha protein 
levels and its transcriptional activity. A) HT29 cells and LS174T cells were 
treated for up to 96 hours with SB (IOjjM) and were collected at the indicated 
time points to analyze HIF-1 alpha protein levels by immunoblotting. The 
inhibition of p38 alpha induced a reduction of HIF-1 alpha protein in a time 
dependent manner, indicating that exist a relationship between the kinase and this 
transcription factor. Actin was used as loading control. The pictures shown are 
representative of three replicates. B) HT29 cells were treated for up to 72 hours 
with SB (lOpM) or DMSO and were collected at the indicated time points. HIF-1 
alpha and HK2 protein levels were evaluated by immunoblotting. This 
experiment elucidated that the absence of HIF-1 alpha it is related to its target 
gene protein. Actin was used as loading control. The pictures shown are 
representative of three replicates.
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data, we treated HT29 cells for up to 72 hours with SB and we also checked for 
the protein levels of the HK2 (Figure 11B). The figure shows that during SB 
treatment there is a strong decrease of the protein level of HK2, which is well 
related to the decrease of HIF-1 alpha protein levels.
Given these results, we investigated whether p38 alpha and HIF-1 alpha could be 
linked. Two papers have established a positive role of p38 alpha in the 
stabilization of this transcription factor, and these authors used MEFs (Emerling 
et al., 2005) and pancreatic cancer cells (Kwon et al., 2005) as model. We took 
advantage of deferoxamine (DFO), a well known drug that mimics the effects of 
hypoxia (Wang and Semenza, 1993), to stabilized HIF-1 alpha and we treated 
HT29 cells for 24 hours with this compound in presence or not of SB. We 
evaluated the protein levels of HIF-1 alpha by immunoblot analysis (Figure 12A). 
As shown by densitometric analysis, DFO treatment was not able to completely 
rescue the degradation effect of SB on HIF-1 alpha protein, indicating that p38 
alpha could play a role in HIF-1 alpha stabilization in CRC cells. Then, we 
evaluated whether p38 alpha also plays a role on the transcriptional activity of 
HIF-1 alpha. We performed the same previous experiment in HT29 cells and we 
analyzed the mRNA levels of HK2 and LDHa (Figure 12B). When the drugs are 
used together, mRNA levels of these genes were similar to those in which DFO is 
used alone, indicating that p38 alpha could be not involved in this process. This 
result is in agreement with Emerling and colleagues that used a luciferase assay 
to demonstrate that p38 alpha was not involved in the transcriptional activity of
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Figure 12. p38 alpha inhibition affected HIF-1 alpha protein stability but not 
its dependent transcription. A) HT29 cells were treated for 24 hours with 
DMSO, SB (lOjiM), DFO (lOOpM) and DFO plus SB. The graph indicates the 
ratio between the band intensity of each experimental point (SB, DFO and 
DFO/SB) and control (DMSO) for HIF-1 alpha. The stabilization by DFO of 
HIF-1 alpha protein is disrupted during p38 alpha inhibition. Actin was used as 
loading control. Comparison between densitometry of each treatment and DMSO 
treated cells was performed using a student’s t test followed by Mann-Witney U 
test (*=p<0.05). Results are expressed as mean ±SEM (n=3). B) HT29 cells were 
treated for 24 hours with DMSO, SB (lOjiM), DFO (lOOpM) and DFO plus SB. 
The graph shows mRNA levels of two HIF-1 alpha target genes (HK2 and 
LDHa). HIF-1 alpha transcriptional activity was not affected when DFO and SB 
are used together, indicating that p38 alpha is not involved in HIF-1 alpha 
dependent transcription. The relative mRNA levels are expressed as fold 
induction, beta-actin was used as calibrator of mRNA quantity. Comparison 
between densitometry of each treatment and DMSO treated cells was performed 
using a student’s t test followed by Mann-Witney U test (*/**=p<0.05). Results 
are expressed as mean ±SEM (n=3).
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HIF-1 alpha but only with its stabilization (Emrling et al., 2005). All these 
experiments indicated that the inhibition of p38 alpha in CRC cell lines induces a 
decrease of the glycolityc pathway. Indeed, the inhibition of this kinase produces 
a strong reduction of HIF-1 alpha protein and the transcription of the most 
important glycolityc genes, depriving these cells of the fastest "fuel" for survival. 
In CRC cells SB treatment promotes a significant upregulation of genes that 
regulate autophagy, cell cycle progression and cell death (Comes et al., 2007). 
Starting from this observation we decided to analyzed a greater number of genes 
related to these pathways and we treated HT29 cells for 96 hours with SB and we 
performed a real time PCR to detected the changes of their mRNA levels (Figure 
13A-C). Interestingly, we found that upon p38 alpha blockade the autophagic 
genes homolog of yeast ATG8, such as GABARAP, GABARABPL1 and 
MAP1LC3, and other ATG genes were upregulated in a time-dependent manner, 
indicating that the inhibition of p38 alpha induced a strong energy demand, 
probably due to the blockade of glycolysis. Moreover, also the genes related to 
cell cycle arrest, such as p21 and p27, and to cell death, such as BIM  and 
GADD45 were upregulated in a time dependent manner. Worth of note is that the 
genes involved in the progression of cell cycle, such as CYCA2 and CYCD1, were 
downregulated, confirming that the inhibition of p38 alpha induced autophagy, 
cell cycle arrest and cell death (Comes et al., 2007). Since this analysis revealed a 
strong reprogramming in CRC cell lines during p38 alpha inhibition, we decided 
to explore the possibility that one or more transcription factors might be triggered
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Figure 13. SB-treatment in HT29 cells induced upregulation of genes 
involved in autophagy, cell cycle arrest and cell death. A-C) HT29 cells were 
treated with SB (lOpM) for up to 96 hours. During SB treatment, mRNA levels 
of genes related to autophagy, cell cycle arrest and cell death are upregulated. 
Interestingly, gene related to cell cycle progression were downregulated during 
p38 alpha inhibition. The relative mRNA levels are expressed as fold induction, 
beta-actin was used as calibrator of mRNA quantity. Results are expressed as 
mean ±SEM (n=3).
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in this scenario. Thus, my colleagues made use of the “CONFAC” software 
(Karanam and Moreno, 2004) to perform an in silico analysis of the promoters of 
these genes and they found that the SB treatment-responsive genes were 
significantly enriched in the conserved consensus core recognition motif FHRE, 
which is specific for Fox03A, indicating that this transcription factor could play 
a role during SB treatment of CRC cells. To evaluate whether Fox03A is 
activated in this scenario, we decided to analyzed the pathways that control the 
localization of this protein in the cells. It is worth noting that AKT is a negative 
regulator of FoxO family, while AMPK has a positive role in its regulation, 
recruiting the members in the nucleus (Greer et al., 2007). To ascertain whether 
these pathways were involved in Fox03A activation during p38 alpha inhibition, 
we treated HT29 cells for up 96 hours and we performed an immunoblot analysis 
to verify the activation status of these upstream regulators of Fox03A (Figure 
14). Significantly, we found that throughout the inhibition of p38 alpha, AKT is 
not phosphorylated while AMPK is phosphorylated in a time-dependent manner. 
Moreover, the protein levels of PTEN, a negative regulator of PI3K/AKT 
pathway (Maehama and Dixon, 1999), resulted increased. This experiment 
showed that Fox03A regulating pathways were modified during SB treatment 
triggering its activation. To better understand the role of AMPK in this scenario, 
we treated HT29 cells with SB with or without the AMPK inhibitor Compound C 
(CC) for 24 hours (Figure 15). The inhibition of AMPK abrogates the induction 
of Fox03A-target genes induced by p38 alpha inhibition, indicating that this 
kinase plays a role in the Fox03A-dependent transcription during SB treatment.
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Figure 14. p38 alpha inhibition modulated FoxO regulating pathways . HT29 
cells and LS174T cells were treated with lOpM of SB for up to 96 hours. Cells 
were collected at the indicated time points and analyzed for the amount of protein 
levels of phosphorylated and total form of AKT, AMPK and PTEN. The numbers 
indicate the ration of phosphorylated form versus the total amount of protein. As 
indicated by the ratio, the inhibition of p38 alpha induced modification in the 
phosphorylation status of AKT and AMPK kinases and the accumulation of the 
tumor suppressor PTEN. This immunoblot indicates that during SB-treatment 
AKT is inhibited while AMPK is activated. Actin was used as loading control. 
The pictures shown are representative of three replicates.
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Figure 1R. SB-treatment induced upregulation of Fox03A-target genes in 
HT29 cells in AMPK-dependent manner. HT29 cells were treated for 24 hours 
with SB (lOjiM) with or without Compound C (CC, 10pM), to relate AMPK 
activation to Fox03A-dependent transcription. When AMPK is inhibited during 
SB treatment, this kinase failed to activate Fox03A-dependent transcription, 
beta-actin was used as calibrator of mRNA quantity. Comparison of mRNA 
levels of genes indicated in the graph between SB-treated and SB/CC- treated 
cells was performed using a student’s t test followed by Mann-Witney U test 
(*=/?<0.05). Results are expressed as mean ±SEM (n=3).
103
Moreover, my colleagues demonstrated that the silencing of AMPK by siRNA 
assay abolished the nuclear localization of Fox03A in HT29 cell line during SB 
treatment (Chiacchiera et al., 2009). All these data indicated that p38 alpha 
inhibition in CRC cellsproduced an impairment in the glycolytic pathway. This is 
related with the decrease of HIF-1 alpha protein level and its related 
transcriptional activity. Moreover, SB treatment positively regulates the 
Fox03A-dependent transcription of genes involved in autophagy, cell cycle 
arrest and cell death by acting on the AMPK and PI3K/AKT pathways
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4.2 The role of p38 alpha in ovarian cancer
The inhibition of p38 alpha impairs key metabolic functions of CRC cells, 
inducing growth arrest, autophagy, and cell death both in vivo and in vitro 
(Comes et al., 2007; Chiacchiera et al., 2009). These effects are mediated by a 
switch from HIF-1 alpha to Fox03A-dependent transcription (Chiacchiera et al., 
2009). These results prompted us to ascertain whether other tumors are sensitive 
to p38 alpha inhibition. To this end, we tested SB activity in other types of 
malignancies, focusing on cancers in which the role of HIF-1 alpha has been well 
documented, such as those originating in the ovary (Osada et al., 2007).
For this purpose, we first evaluated the expression pattern of p38 isoforms in 
OvCa cell lines, evaluating the mRNA of the four p38 isoforms in OVCAR-3, 
A2780, and SKOV-3 OvCa cell lines by a semiquantitative analysis (Figure 
16A). This experiment revealed that p38 alpha represents the main isoform in 
these cells, such as in CRC cells. Because SB specifically inhibits p38 alpha and 
p38 beta, we analyzed the relative abundance of the mRNA of these two isoforms 
by quantitative RT-PCR in OVCAR3 cells (Figure 16B). We confirmed that p38 
alpha is highly expressed, whereas p38 beta is not detectable. Then, we measured 
the basal levels of the activated form of p38 in these cells by immunoblot 
analysis (Figure 16C). When compared with primary human fibroblasts, which 
express both the alpha and beta isoforms of p38 at levels comparable to those 
detected in cancer cells but are insensitive to SB (Comes et al., 2007), OVCAR-3 
cells were found to display an aberrant activation of p38, similar to that detected
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Figure 16. p38 alpha is required for OvCa cell homeostasis. Characterization 
of the expressions of the p38 alpha, beta, gamma and delta isoforms in HT29, 
OVCAR-3, A2780, and SKOV-3 cell lines. A) Multiplex RT-PCR analysis was 
performed to evaluate the amount of each p38 isoforms, beta-actin was used as 
calibrator of mRNA quantity. B) The relative levels of expression of the p38 
alpha and beta isoforms were measured by quantitative real-time PCR analysis in 
HT29 cells and OVACR-3 cells, beta-actin was used as calibrator of mRNA 
quantity. Results are expressed as mean ±SEM (n=3). C) Activation state of p38 
in HT29 cells, OVCAR-3 cells and human fibroblasts (hFSF). The values are the 
results of the densitometric analysis of the phosphorylated form of p38 
normalized against p38 total. Actin was used as loading controls. Results are 
expressed as mean ±SEM (n=3).
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in HT29 cells. These results prompted us to inhibit p38 alpha in the three OvCa 
cell lines.To test the effects of SB treatment in OvCa cells, we treated for up to 
72 hours with SB or DMSO OVCAR-3, A2780, and SKOV-3 cells and we 
evaluated the morphological changes in these cell lines by optical microscope 
(Figure 17). Significantly, the exposure to SB induced the formation of large 
intracellular vacuoles and reduced the number of cells compared with DMSO- 
treated cells. As in CRC, we decide to explore the possibility that the inhibition 
of this kinase could affect the protein levels of HIF-1 alpha. To this purpose we 
treated OVCAR-3 cells with SB for up to 48 hours and we analyze the protein 
levels of HIF-1 alpha and of HK2 (Figure 18A). We found that HIF-1 alpha and 
HK2 protein levels decreased in a time-dependent manner, thus indicating that 
also in OvCa cells the inhibition of this kinase could play a role in HIF-1 alpha 
stabilization. We also treated OVCAR-3 cells with SB for up to 72 hours to 
evaluate the expression profile of HIF-1 alpha targets genes HK2 and PKM2 
(Figure 18B). These genes resulted down-regulated by p38 alpha blockade in 
OVCAR-3 cells. These data, similar to CRC cell lines, suggest that p38 alpha 
could be involved in HIF-1 alpha stabilty also in OvCa cells. Since in CRC cell 
lines the inhibition of p38 alpha induced a block in HIF-1 alpha-dependent 
transcription triggering a Fox03A-dependent transcription, after nuclear 
localization and activation of this trascription factor (Chiacchiera et al., 2009). 
We treated OVCAR-3 cells with SB for up to 72 hours and we analyzed the 
activation status of Fox03A regulators and Fox03A transcriptional activity 
(Figure A-D). SB treatment significantly reduced the inhibitory phosphorylation
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Figure 17. Morphological evaluation of three OvCa cell lines. OVCAR-3, 
A2780, and SKOV-3 cells were treated or not (DMSO) with SB (lOpM) for up 
to 72 hours. SB treatment reduces the number of cells and increased the number 
of vacuolated cells. Representative pictures of three replicates were taken at the 
time points indicated.
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Figure 18. p38 alpha sustains HIF-1 alpha protein expression and its 
dependent transcription. A) OVCAR-3 cells were treated with SB (IOjiM) for 
up to 48 hours. HIF-1 alpha and HK2 protein levels were analyzed by 
immunoblot. The inhibition of p38 alpha reduced the amount of HIF-1 alpha and 
HK2 protein levels. The numbers are the ratio of the densitometric analysis of the 
protein levels in DMSO treated cells and in SB-treated cells and actin. Actin was 
used for loading control. The pictures shown are representative of three 
replicates. B) OVCAR-3 cells were cultured with SB (10pM) for up to 72 hours. 
Quantitative real-time PCR analysis of HIF-1 alpha target genes HK2 and PKM2 
involved in glycolysis was performed, beta-actin was used as calibrator of mRNA 
quantity. Results are expressed as mean ±SEM (n=3). Comparison of mRNA 
levels of genes evaluated during the treatment with SB was performed using a 
student’s t test followed by Mann-Witney U test (*=/?<0.05).
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by AKT of Fox03A. Importantly, this time-dependent reduction in 
phosphorylated
Fox03A is related to the reduction in AKT phosphorylation. Conversely, AMPK 
was significantly phosphorylated in OVCAR-3 cells. These findings depicted a 
scenario very similar to CRC cells during SB treatment. Consistently, all 
Fox03A target genes tested, some of which code for proteins playing a role in 
autophagy such as MAP1LC3, GABARAPL1, and GABARAP, and others genes 
involved in cell cycle control and cell death, were significantly up-regulated by 
p38 alpha blockade Among the cell cycle regulators, we detected a significant 
induction of the cyclin-dependent kinase inhibitors p21 and p27, the 
retinoblastoma family protein retinoblastoma-like 2 (RBL2), and the
transcriptional repressor BCL-6. Moreover, we detected the down-regulation of 
the genes coding for Cyclins E  and A2.
Since the inhibition of p38 alpha in CRC cell lines induced a perturbation in the 
viability and an increase of cell death with autophagic features (Comes et al., 
2007), our purpose was to analyze whether also in OvCa cells SB treatment 
produced the same results. We treated OVCAR-3, A2780, and SKOV-3 cells for 
72 hours with SB and we performed a colony formation assay (Figure 20A). As 
shown in the picture, we found that there was a strong reduction in number of 
colonies in each cell line. After this result we treated OVCAR-3 cells for up to 72 
hours with SB to analyzed the cause of this decrease and we performed a WST-1 
analysis and a cellular count with trypan blu (Figure 30B-D). SB treatment
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Figure 19. SB switches the activation of signaling pathways promoting 
FoxO-dependent transcription. OVCAR-3 cells were treated with SB (IOjiM) 
for up 72 hours (A) and for up to 48 hours (B,C). Immunoblot analysis was 
performed to evaluate the phosphorylation status of Fox03A (A), AKT (B) and 
AMPK (C). The inhibition of p38 alpha induced the decrease of inhibitory 
phosphorylation of Fox03A (A) and the decrease of AKT phosphorylation (B). 
Conversely, AMPK is activated (C). The numbers are the ratio of the 
densitometric analysis of the phosphorylated amount of the indicated proteins 
normalized against their total amount and actin. Actin was used for loading 
control. The pictures shown are representative of three replicates. D) OVCAR-3 
cells were cultured in the absence or the presence of SB (lOpM) for up to 72 
hours. Quantitative real-time PCR analysis of Fox03A target genes involved in 
autophagy, cell cycle arrest, and cell death was performed. p38 alpha blockade 
induces the expression of Fox03A target genes involved in these pathways. Cell 
cycle progression genes (eye E  and eye A2) are indirect targets, beta-actin was 
used as calibrator of mRNA quantity. Results are expressed as mean ±SEM 
(n=3). Comparison of mRNA levels of genes evaluated during the treatment with 
SB was performed using a student’s t test followed by Mann-Witney U test 
(*=7?<0.05).
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Figure 20. p38 alpha inhibition affects OVCAR-3 proliferation and survival.
A) OVCAR-3, A2780, and SKOV-3 cell lines were treated with or without SB 
(IOjjM) for 72 hours. Colony formation assay was performed. Cell were stained 
with Coomassie blue. Colored cells are living cells. The inhibition of p38 alpha 
affected the cell number of these three OvCa cell lines. Representative pictures of 
three replicates were taken. B) OVCAR-3 cells were treated with or without SB 
(lOpM) for up to 72 hours. OVCAR-3 cell growth was quantified using the 
WST-1 cell proliferation assay. The inhibition of proliferation during SB 
treatment was confirmed in OVCAR-3 cells. Results are expressed as mean 
±SEM. C-D-E) OVCAR-3 cells were treated with or without SB (lOpM) for up 
to 72 hours. C) Relative viability (percent) was estimated by calculating the ratio 
between the viable cells of treated cells (SB) versus those of DMSO treated cells. 
Results are expressed as mean ±SEM (n=3). Comparison of viable cells between 
treated (SB) and DMSO treated cells was performed using a student’s t test 
followed by Mann-Witney U test (*=p<0.05). D) Relative cell death (percent) 
represents the ratio between the dead cells in the treated cells versus those in the 
untreated OVCAR-3 cells. Results are expressed as mean ±SEM (n=3). 
Comparison of dead cells between treated (SB) and DMSO treated cells was 
performed using a student’s t test followed by Mann-Witney U test (*=/7<0.05). 
E) The percentage of autophagic cells was estimated by phase-contrast 
microscopy. More than 100 cells were used for this evaluation. Results are 
expressed as mean ±SEM (n=3). Comparison of vacuolated cells between SB- 
treated and DMSO treated cells was performed using a student’s t test followed 
by Mann-Witney U test (*=p<0.05).
112
induced a strong reduction of cell number, as indicated by the low value of 
absorbance of the WST-1 assay and this is related to a decrease in viability and to 
an increase of cell death in a time-dependent manner. We checked also whether 
SB treatment induced the same autophagic vacuolation of CRC cells. To this 
purpose we treated OVCAR-3 cell for up to 72 hours and we counted the number 
of vacuolated cells (Figure 20E). This experiment showed that there was a time- 
dependent autophagic vacuolation, similar to CRC cells, from the first hours of 
SB treatment, affecting more that 80% of cells at 24 hours and reaching almost 
100% at 48 and 72 hours. These results, together with the AMPK activation and 
the transcription of Fox03A-dependent autophagic genes could suggest that 
inhibition of p38 alpha caused autophagic cell death also in OvCa cells.
All these data confirmed once again that inhibiting p38 alpha, in tumors which 
displayed an overactivation of this kinase, induced autophagy, cell cycle arrest 
and cell death. This scenario is due to the degradation of HIF-1 alpha and the 
activation of Fox03A-dependent gene transcription.
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4.3 Prostate cancer and p38 alpha inhibition
Besides CRC and OvCa, we decided to test the efficacy of the p38 alpha 
inhibition also on prostate cancer, which is another tumor that depends on HIF-1 
alpha for sustaining (Khandrika et al., 2009). We employed two widely used PCa 
cell lines, DU 145 and PC3. As for CRC cells and OvCa cells, to determine which 
was the most abundant isoform among the members of p38 family we performed 
a multiplex PCR for all four isoforms in these cell lines (Figure 21 A). Once 
verified that p38 alpha was the most abundant one, we treated DU 145 cells and 
PC3 cells for up to 72 hours with SB and we performed an immunoblot analysis 
to check the phosphorylation status of MK2 (Figure 21B). This experiment 
showed that MK2 was not phosphorylated in both cell line when p38 alpha was 
inhibited, indicating that this kinase is inhibited. However, we can not explain the 
differences in the MK2 basal phosphorylation status between the two cell lines. 
Further analysis are necessary. Since in CRC cells and OvCa cells the inhibition 
of p38 alpha affected HIF-1 alpha protein levels and its dependent transcription, 
DU145 cells were cultured for up to 72 hours with SB to evaluate HIF-1 alpha 
protein levels and its transcriptional activity (Figure 22A and B}. This experiment 
showed a decrease of HIF-1 alpha protein level which came together with the 
decreased expression of three glycolytic genes in a time-dependent manner.
Next step of our analysis was to evaluate the citotoxic effect of p38 alpha 
inhibition on PCa cell lines. To this purpose, we treated both cell lines with SB or 
not for up to 96 hours and we performed a cellular count using trypan blue dye
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Figure 21. Analysis of isoforms and activity of p38 alpha in PCa cells. A) A
multiplex PCR for the four isoforms of p38 in PCa cells was performed. The 
abundant isoform in these two prostatic cancer cell lines is alpha. The pictures 
shown are representative of three replicates. B) PCa cell lines were treated with 
SB (lOpM) for up to 72 hours. Immunoblot for the activation status of p38 alpha 
was performed. In both cell lines p38 alpha is blocked by SB administration, as 
shown by the not phosphorylated status of MK2 during this treatment. Actin was 
used as loading control. The pictures shown are representative of three replicates.
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Figure 22. p38 alpha inhibition affects HIF-1 alpha protein levels and its 
transcriptional activity. A) DU 145 cells were treated with SB (IOjxM ) for up to 
72 hours. Immunoblot analysis of HIF-1 alpha protein was performed. As in CRC 
and OvCa cell lines, p38 alpha inhibition affects the protein levels of HIF-1 alpha 
protein. Actin was used as loading control. The pictures shown are representative 
of three replicates. B) DU 145 cells were treated with SB (IOjjM ) for up to 72 
hours. Real time PCR of the most important glycolytic genes ('GLUT1, PKM2 
and LDHa) was performed. The decrease of HIF-1 alpha protein levels is 
reflected by the downregulation of its glycolytic target genes, beta-actin was used 
as calibrator of mRNA quantity. Results are expressed as mean ±SEM (n=3). 
Comparison of mRNA levels of these genes between treated (SB) and DMSO 
treated cells was performed using a student’s t test followed by Mann-Witney U 
test (*=/?<0.05).
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(Figure 23 A,B). Surprisingly, the treatment had different outcomes between the 
two cell lines; indeed, DU 145 cells revealed a strong reduction in cell number 
after 48 hours of treatment, while PC3 cells were still able to grow, but at a 
reduced rate compared to DMSO-treated cells. This result was confirmed by the 
percentage of cell death, which increased in DU145 cells, especially after 48 
hours of SB treatment, but remained unchanged in SB-treated PC3 cells. 
Moreover, we treated these two cell lines with SB or DMSO for up to 96 hours 
and we performed a WST-1 analysis (Figure 24). This experiment confirmed that 
p38 alpha inhibition induced different effects in these two cell lines, as 
demonstrated by the diverse value of absorbance. Indeed, DU 145 cells showed a 
decreased of this value, indicating a reduction of cell number, while in PC3 cells 
this value slowly increased, indicating that they are proliferating. To investigate 
the causes of these different responses in PCa cells to p38 alpha inhibition, we 
performed immunoblot analysis of dul45 cells and PC3 cells treated with SB for 
up to 72 hours and we checked for the modulation of relevant pathways altered in 
SB-treated CRC cells and OvCa cells (Figure 25A). Importantly, we detected a 
significant difference in AMPK activation between the two cell lines, while the 
modulation of AKT pathway is almost similar. Even if the basal levels of total- 
AKT are different in DU 145 and PC3 cells, possibly due to PTEN mutations in 
PC3 cells, its phosphorylation decreased in a time-dependent manner upon p38 
alpha inhibition in both cell lines while AMPK was not activated by SB treatment 
in DU145 cell line. The strong difference in AMPK phosphorylation status led us 
to check known modifications in the AMPK pathway and we decided to
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Figure 23. Evaluation of p38 alpha inhibition on cell proliferation and 
viability of PCa cells. DU 145 cells and PC3 cells were treated for up to 96 hours 
with SB (lOpM) and every 24 hours a cellular count was performed using trypan 
blue assay. A) p38 alpha inhibition exerted two different outcomes, the decrease 
in cell number in DU145 cells especially after 48 hours of incubation, while a 
slow proliferation in PC3 cells. Results are expressed as mean ±SEM (n=3). B) 
The differences in cell number is due to a strong cell death in DU 145 cells while 
there is only a slight cell death in PC3 cells. Results are expressed as mean ±SEM 
(n=3). Comparison of dead cells between treated (SB) and DMSO treated cells 
was performed using a student’s t test followed by Mann-Witney U test 
(*=/?<0.05).
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Figure 34. SB treatment induced cell death in DU14R cells and growth arrest 
in PC3 cells. DU 145 cells and PC3 cells were treated for up to 96 hours with SB 
(lOpM) or DMSO. Cell growth was quantified using WST-1 cell proliferation 
assay. This assay confirmed the two different outcomes of SB treatment in these 
cell lines on cell proliferation. The data shown are the mean of three different 
experimental settings. Results are expressed as mean ±SEM.
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investigate whether DU 145 and PC3 cells differ in LKB1 status. LKB1 is a well 
known AMPK upstream kinase (Shaw et al., 2004; Sakamoto et al., 2005), it is 
mutated in several cancer types (Wingo et al., 2009; Ji et al., 2007) and 
inactivated in the PJS (Giardiello et al., 2000). To this purpose, we performed an 
immunoblot analysis for LKB1 protein in PCa cells and HT29 cells, wild type for 
LKB1 protein (Figure 35B). The picture clearly shows that DU 145 cells are null 
for this kinase. Thus, to induce the activation of AMPK in DU 145 cells we 
decided to use its activator AICAR (Merrill et al., 1997). We treated DU 145 cells 
and PC3 cells with AICAR and SB for 72 hours and we analyzed by immunoblot 
analysis the activation status of AMPK (Figure 36). The picture shows that 
AICAR failed to activate AMPK in DU 145 cells, as indicated also by the fact that 
Acetyl CoA Carboxilase (ACC), target of AMPK (Witters et al., 1991), is not 
phosphorylated. Conversely, in PC3 cells AMPK is activated by AICAR, such as 
during SB treatment, since ACC was phosphorylated, indicating that LKB1 is 
necessary to activate AMPK in PCa cells. Since in CRC and OvCa cells SB 
treatment induced activation of autophagic pathway (Comes et al., 2007;(Matrone 
et al., 2010), and AMPK is a key regulator of autophagy (Meley et al., 2006), we 
decided to investigate whether there were changes in autophagic pathway 
activation. We treated DU 145 cells and PC3 cells with SB for 72 hours and we 
performed an immunoblot for the marker of autophagy LC3. Contemporaneously, 
we decided to analyzed also the apoptotic pathway and we checked for the 
protein levels of p85 (Figure 27). This immunoblot analysis shows that PC3 cells 
(wild type for LKB1) were able to induce autophagy, as revealed by the increase
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Figure 2R. The inhibition of p38 alpha modulated AMPK and AKT 
pathways in PCa cells. A) PCa cell lines were treated for up to 72 hours with SB 
(IOjiM) and a immunoblot of phosphorylation status of AKT and AMPK was 
performed. The inhibition of p38 alpha in DU 145 and PC3 exerted different 
outcomes regarding the phosphorylation status of AMPK while the decrease in 
the phosphorylation status of AKT resulted similar between the two cell lines. 
Actin was used as loading control. The pictures shown are representative of three 
replicates. B) Immunoblot of LKB1 in different cancer cell lines. As shown in the 
figure, DU 145 are null for the upstream kinase of AMPK. Actin was used as 
loading control. The pictures shown are representative of three replicates.
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Figure 26. AICAR failed to phosphorylate AMPK protein in DU14R cells.
DU145 cells and PC3 cells were incubated for 24 hours with DMSO, SB (lOpM) 
and AICAR (500|jM). Neither SB or AICAR were able to induce AMPK 
phosphorylation in DU145 cells (LKB1 null). This is confirmed by the not 
phosphorylated status of AMPK target protein AcetylCoA Carboxylase (ACC). 
Conversely, these two drugs activated AMPK in PC3 cells (LKB1 wild type). 
Actin was used as loading control. The pictures shown are representative of three 
replicates.
122
of the lipidated form of LC3 (II), but not apoptosis; conversely, DU 145 cells 
(LKB1 null) were not proficient for autophagy but underwent apoptosis, as 
indicated by the increase of p85. This experiment suggests that AMPK plays a 
role in the activation of autophagy in PCa cells during SB-treatment. Moreover, 
p38 alpha inhibition in PCa cell lines lacking AMPK activation seemed to trigger 
apoptosis, that could be the causes of cell death in DU145 cells. Since the LKB1 
status could be important to induce cell death in prostate cancer with SB 
treatment, we tested this molecule on primary cells taken from biopsies of one 
patient null for LKB1 and another with a LKB1 wild type, after the evaluation of 
LKB1 status by an immunohistochemistry (IHC) (data not shown). These cells 
were treated for up to 96 hours with SB and a cell count with trypan blue was 
performed (Figure 28). LKB1 null primary cells showed a percentage of cell 
death (60% circa) higher than LKB1 positive cells (30%).
For this experiment we thank our colleagues of the Policlinico of Bari, which 
made biopsies, the IHC of LKB1 and the cell count.
p38 alpha inhibition in PCa did not showed the same results of CRC and OvCa 
cell lines. This is a very interesting point because revealed that in PCa cells 
LKB1 plays an important role in this tumor. Indeed, this kinase seemed to be 
involved in the autophagic activation in these cell lines but, also, seemed to be 
protective, since its absence induced apoptotic cell death during SB treatment.
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Figure 27. SB treatment increased apoptotic pathway in DU14R cells and 
autophagic pathway in PC3 cells. DU 145 cells and PC3 cells were cultured for 
72 hours with or without SB (lOpM). Immunoblot for p85 and LC3 was 
performed. The inhibition of p38 alpha increased the protein levels of p85 only in 
DU145 cells, indicating that the cell death described before (see Figures 33 and 
34) is apoptotic death. Interestingly, in DU145 LC3 II, the marker of autophagy, 
did not accumulate, excluding this pathway in SB treatment outcomes. 
Conversely, PC3 cells shown the characteristic pattern of SB treatment similar to 
CRC cells and OvCa cells. Actin was used as loading control. The pictures shown 
are representative of three replicates.
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Figure 28. Primary cells of human biopsies treated with SB shown the 
similar pattern of PCa cells. For this experiment were used primary human cells 
taken from biopsies of patients affected by PCa, which were positive or null for 
LKB1 protein by immunohistochemistry, to replicate the genetic condition of 
PCa cell lines. These cells were treated with SB (lOpM) for up to 96 hours. At 
the indicated time points cell were counted using trypan blue assay to ascertain 
the cell death. As indicated in the figure, the primary cells taken from human 
prostatic biopsy LKB1 null shown a percentage of cell death greater than human 
biopsy cells LKB1 positive, indicating how LKB1 could play a role in the SB- 
dependent cell death. Normal prostatic cells were used as control. Results are 
expressed as mean ±SEM (n=3). Comparison of dead cells between treated (SB) 
and DMSO treated cells was performed using a student’s t test followed by 
Mann-Witney U test (*=/?<0.05).
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4.4 Colorectal cancer and chemotherapy
Cisplatin (CDDP) is one of the most effective and commonly used 
chemotherapeutics for the treatment of many solid tumors, including ovarian, 
testicular, bladder, lung, head, neck and colorectal tumors (Siddik, 2003; 
Boulikas and Vougiouka, 2003). Unfortunately, parallel to high efficacy in the 
treatment of the above tumors, the development of resistance to CDDP-based 
therapy is a major obstacle for its successful clinical application. In the majority 
of investigated tumors, resistance to CDDP is generally multifactorial. CDDP, 
such as other most common chemotherapeutics, results ineffective due to 
chemoresistance, which could be acquired or dependent by genetic mutations. 
Recently, different groups demonstrated that chemotherapeutics such as 5-FU 
(Yang et al., 2011) or CPT-11 (Paillas et al., 2011) in CRC are able to induce p38 
alpha phosphorylation. In both cases, its inhibition led to cell death, suggesting 
that p38 alpha could overcome chemorestistance.
In this study we evaluated the role of p38 alpha in CDDP cellular response in 
two CRC cell lines. We chose HT29 cells and HCT116 cells as model for our 
investigation, since several studies (Fernandez de et al., 2008; Arango et al., 
2004) showed that these two CRC cell lines have different outcomes when 
treated with platinum-compounds, reveling that HT29 cells are less sensitive than 
HCT116 cells, probably due to the different status of p53 gene. Indeed, this gene 
is mutated in HT29 cells and wild type in HCT116 cells. First at all, we checked 
whether CDDP was able to induce activation of p38 alpha. For this reason the
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two CRC cell lines were treated for 48 hours with 30uM of CDDP and p38 
phosphorylation status was evaluated by immunoblot (Figure 29). CDDP induced 
p38 phospho-activation in both cell lines, and this activation is underlined by the 
phosphorylation of its well known direct target MK2.
Once verified that CDDP was able to induce p38 alpha activation in both cell 
lines, next step of our analysis was to understand the effect of its inhibition on 
cell behavior. We treated HCT116 cells and HT29 cells for 48 hours with SB and 
CDDP alone and in combination.
To evaluate the effect of these treatments the cells were stained with Comassie 
brilliant blue, directly in the colture dishes. Only live cells remained attached and 
were blue stained. Assuming that DMSO-treated cells were 100% of stained cell, 
it is possible to compare the stained cells between the various treatments (Figure 
30). As shown in the figure, the percentage of stained HCT116 cells was 35% 
with the only CDDP while during the co-treatment decreased to 18%. 
Conversely, stained HT29 cells were 87% with CDDP alone while surprisingly 
during the co-treatment were only the 16%. These data confirmed that CDDP has 
two different outcomes in these CRC cell lines while the co-treatment greatly 
reduce the number of stained HCT116 cells, and of stained HT29 cells. These 
results indicated that the inhibition of p38 alpha during the administration of 
CDDP enhanced its effect in HCT116 cells while made HT29 cells sensitive to 
this chemotherapeutic. The low percentage of relative stained cells during co­
treatment led us to understand whether the combination of SB with CDDP 
induced an impact on cell cycle or an increase of cell death, To answer this
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Figure 29. CDDP treatment activates p38 alpha kinase. HCT116 cells and 
HT29 cells were treated for 48 hours with CDDP and cells were collected and 
analyzed by immimoblotting to evaluate the activation of p38 alpha. The 
phosphorylation status of p38 alpha increased after CDDP treatment and its 
activity is underlined by the phosphorylation status of its downstream target 
MK2. The pictures shown are representative of three replicates. Actin was used 
as loading control.
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Figure 30. Macroscopic effect of CDDP and SB compounds on HCT116 and 
HT29 cell lines. HCT116 cells and HT29 cells were treated for 48 hours with 
DMSO, SB (lOpM), CDDP (30pM) and CDDP plus SB. After 48 hours of 
treatment, cells were washed with PBS and then stained with Comassie brilliant 
blue. Only the live cells were blue stained. The graphs indicate that HT29 cells 
were less responsive to CDDP than HCT116 cells, while when CDDP is used 
together with SB both cell lines shown a strong reduction of live cells. The 
graphs indicate the ratio of blue cells between DMSO and each treatment. 
Untreated cells were considered 100%. Results are expressed as mean ±SEM 
(n=3). Comparison of percentage of blue cells between SB-treated and DMSO 
treated cells was performed using a student’s t test followed by Mann-Witney U 
test (*=/?<0.05).
100g.
80
jg
60©.>
as 40oEC 20
0
129
question we treated HCT116 cells and HT29 cells for up to 96 hours with SB and 
CDDP alone or in combination and we performed a cellular count, using trypan 
blue assay. In this case this dye stained the dead cells, turning them blue at the 
optical microscopy. At the indicated times, we counted the number of blue cells 
(dead cells) and the number of non-blue cells (living cells) for each treatment 
(Figure 31A,B). As regard the percentage of viable cells, the combination of SB 
and CDDP was able to reduce it dramatically in both cell lines and in a time- 
dependent manner, compared with the two compounds alone; similarly, we 
counted a very strong increase in the percentage of cell death in HCT116 cells 
and in HT29 cells during the co-treatment. These data indicated that the 
combination of SB and CDDP affected the number of cells in both cell lines 
through the induction of cell death.
Starting from this observation, the next step of our analysis was to investigate the 
type of cell death. It is well known that CDDP induces apoptotic cell death 
(Fisher, 1994) while SB is a molecule which causes cell death with autophagic 
features (Comes et al.,2007). We cultured HCT116 cells and HT29 cells for 48 
and 72 hours with CDDP and SB alone or in combination and we performed a 
protein analysis to investigate whether the cell death was apoptotic cell death or 
autophagic cell death (Figure 32). We detected the levels of the two most known 
caspases: caspase 8 and caspase 3. Caspase 8, one of the initiator caspases, is the 
protein upstream of caspase 3, which is considered the “effector” of apoptotic 
pathway (Boatright and Salvesen, 2003). To underline the activity of these 
caspases, we analyzed the levels of cleaved PARP-1 (p85). When the apoptotic
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Figure 31. The co-treatment of HCT116 cells and HT29 cells induces the 
increase of cell death. HCT116 cells and HT29 cells were treated with DMSO, 
SB (10pM), CDDP (30pM) alone or in combination with SB for up to 96 hours. 
Every 24 hours, cells were collected and counted using trypan blue dye to 
evaluate the number of live and dead cells. A) In the graphs is shown that co­
treatment induced a strong reduction of viable cells in both cell lines. This 
decrease is bigger than the decrease of compounds alone. Relative viability (%) 
was evaluated with the ratio between viable cells in treated (SB, CDDP, CDDP 
and SB) versus DMSO treated cells. Results are expressed as mean ±SEM (n=3). 
Comparison of percentage of live cells among each treatment was performed 
using a student’s t test followed by Mann-Witney U test (*/**=p<0.05). B) In the 
graphs is shown that co-treatment induced an increase of cell death in both cell 
lines. This increase is bigger than the increase of compounds alone. Relative cell 
death (%) represents the ratio between dead cells in treated (SB, CDDP, CDDP 
and SB) versus DMSO treated cells. Results are expressed as mean ±SEM (n=3). 
Comparison of percentage of dead cells among each treatment was performed 
using a student’s t test followed by Mann-Witney U test (*/**/?<0.05).
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pathway is activated, this protein is cleaved by caspase 3, producing a fragment 
of 85 KDa (Kaufmann et al., 1993; Casiano et al., 1996). To evaluate the 
activation of autophagic pathway, we chose LC3 (I/II) as marker. The 
accumulation of LC3II indicate that autophagy is activated. (Figure 32A,B). In 
both cell lines, during the co-treatment it is possible to note that the protein levels 
of activated caspase 8 (44-42 KDa and 18 KDa) and activated caspase 3 (19-17 
KDa) were elevated if compared with the compounds alone. This accumulation is 
more evident at 72 hours of administration, confirming the data of cellular count. 
Moreover, it is evident that p85 is accumulated both in HCT116 cells and HT29 
cells during the co-treatment. Conversely, it seems that during the co-treatment, 
the accumulation of the LC3II band was similar to that of SB alone in both cell 
lines. These results indicated that the co-treatment induced the activation of the 
apoptotic pathway in both cell lines, while autophagy seemed to be not involved 
in the cell death. To confirm the activation of the apoptotic pathway, these two 
CRC cell lines were treated for up to 96 hours with SB, CDDP alone and the two 
compounds together. Every 24 hours the activation of apoptotic pathway was 
evaluated using the standard marker of apoptosis annexin V. Annexin V is used 
as a probe to detect cells that have expressed phosphatidylserine (PS) on the cell 
surface, an event found in apoptosis (Koopman et al., 1994; Vermes et al., 1995) 
(FIG). As shown in the figure, CDDP alone strongly activated apoptotic pathway 
in HCT116 cells while had no effect on the in HT29 cells, since the percentage of 
Annexin V was similar to untreated cells and SB-treated cells. It is worth of note 
that SB does not activate apoptosis (Comes et al., 2007).
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Figure 32. The cell death induced by co-treatment is apoptotic cell death.
HCT116 cells and HT29 cells were treated for 48 and 72 hours with DMSO, SB 
(IOjiM), CDDP (30pM) and CDDP plus SB. A) At the indicated time points, 
cells were collected and proteins were analyzed by immunoblot to evaluate the 
activation of apoptotic pathway, using apoptotic markers caspase 3, caspase 8 and 
the cleavage fragment of PARP-1 (p85). The co-treatment (+/+) activated the 
apoptotic pathway in both cell lines in a time-dependent manner, as underlined by 
the accumulation of caspase 3 and caspase 8 and p85 proteins. Actin was used as 
loading control. The pictures shown are representative of three replicates. B) At 
the indicated time points, cells were collected and proteins were analyzed by 
immunoblot to evaluate the activation of autophagic pathway, using the marker 
of autophagy MAP1LC3 (LC3). Worth of note is that cell death is not associated 
to an increase of autophagy, since the accumulation of the lipidated form of LC3 
(LC3II) in co-treated cells is equal to the samples treated only with SB, indicating 
that cell death is due only to the activation of apoptotic pathway. Actin was used 
as loading control. The pictures shown are representative of three replicates.
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Figure 33. FACS analysis confirmed the activation of apoptotic pathway.
The two CRC cell lines were treated for up to 96 hours with DMSO, SB (lOpM), 
CDDP (30pM) and CDDP plus SB. At the indicated time, cells were analyzed for 
the presence of annexin V on the surface of the citoplasmic membrane. This 
effect is a particular feature of the apoptotic pathway. The two graphs show the 
percentage of positive cells to the annexin V, indicating that the co-treatment 
induced apoptosis in both cell lines. Here is shown also that CDDP did not 
activate apoptosis in HT29 cells. Results are expressed as mean ±SEM (n=3). 
Comparison of percentage of annexin V among each treatment was performed 
using a student’s t test followed by Mann-Witney U test (*/**=p<0.05).
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Interestingly, apoptosis is enhanced in HCT116 cells while is induced in HT29 
cells when SB and CDDP are used in combination, highlighting the effect of p38 
alpha inhibition in the reinforcement of apoptosis in the responsive cell line and 
in the induction of apoptosis in the insensitive cell line. To better evaluate the 
role of caspase 8 in the apoptotic cell death, we treated HT29 cells with CDDP 
and SB for 48 hours and then we added in the medium of cells its specific 
inhibitor Z-IEDT-FMK. We performed a protein analysis for p85 to evaluate 
apoptosis activation (Figure 34). The inactivation of caspase 8 led to a decrease 
of p85 fragment accumulation, indicating that caspase 8 is involved in the 
activation of apoptosis during the use of CDDP and SB simultaneously in HT29 
cells. These data suggest that the co-treatment with CDDP and the inhibitor of 
p38 alpha in HT29 cells and HCT116 cells caused apoptotic cell death. In the last 
years an increase number of papers demonstrated that the mechanisms of 
resistance can be overcome through the activation of the transcription factor 
Fox03A (De Mattos. et al., 2008). Moreover, our previous works demonstrated 
that the inhibition of p38 alpha in CRC cells and in OvCa cells induced the 
activation of the transcriptional pattern of Fox03A (Chiacchiera et al., 2009; 
Matrone et al.2009). Given these observations, we evaluated whether Fox03A 
plays a role in the capacity to enhance the cell death in HCT116 cell line and to 
sensitize the resistant HT29 cell line.
We treated both cell lines with the compounds alone or in combination for 48 
hours, and we analyzed at confocal microscopy by an immunofluorescence assay 
the distribution of this transcription factor (Figures 35 and 36). Worth of noting,
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Figure 34. The activation of apoptosis is caspase 8-dependent. HT29 cells 
were treated with CDDP (30pM) plus SB (lOpM) and after 24 hours was added 
to the medium the inhibitor of caspase 8 (Z-IEDT-FMK) for the indicated time. 
Analysis of p85 fragment was performed to evaluate the role of caspase 8 in 
apoptotic pathway activation in these cells. As demonstrated in the figure, the 
inhibition of caspase 8 decrease the accumulation of p85, indicating that this 
caspase plays a role in the apoptotic pathway triggered by the co-treatment in 
HT29 cells. Actin was used as loading control. The pictures shown are 
representative of three replicates.
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Figure 35. Fox03A is present in the nuclei of HCT116 cells when treated 
with CDDP. HCT116 cells were treated for 48 hours with DMSO, SB (lOpM), 
CDDP (30pM), CDDP plus SB. Immunofluorescence analysis of Fox03A 
(green) localization was performed to elucidate the role of this transcription 
factor in CDDP treatment. As shown in the figures, Fox03A accumulated in the 
nuclei of CDDP-treated HCT116 cells, indicating that this transcription factor 
could play a positive role in the response to CDDP. Propidium Iodide (P.I., red) 
was used to stain the nuclei. The pictures shown are representative of three 
replicates. The pictures were taken by confocal microscope. Magnification 60X.
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Figure 36. Fox03A accumulated in the nuclei of HCT29 cells when treated 
with CDDP plus SB. HT29 cells were treated for 48 hours with DMSO, SB 
(lOpM), CDDP (30pM), CDDP plus SB. Immunofluorescence analysis of 
Fox03A (green) localization was performed to elucidate the role of this 
transcription factor in CDDP treatment. As shown in the figures, interestingly 
Fox03A did not accumulate in the nuclei of CDDP-treated F1T29 cells, while it 
accumulated in the nuclei of co-treated cells. This could indicate that the 
inhibition of p38 alpha is important for Fox03A translocation in the nuclei of 
CDDP-treated HT29 cells. Propidium Iodide (P.I., red) was used to stain the 
nuclei. The pictures shown are representative of three replicates. The pictures 
were taken by confocal microscope. Magnification 60X.
138
HCT116 cells shown Fox03A predominantly in the nucleus of DMSO-treated 
cells while HT29 cells presented a homogeneous distribution in the cells. 
Moreover, it seems that in some cells Fox03A is not present in the nuclei of 
HT29 cells. Very interesting was also that when the cells were treated with 
CDDP alone the localization of Fox03A was strongly nuclear in HCT116 cells 
while it seemed that in HT29 cells it was homogeneous yet. However, when SB 
is used together with CDDP, the nuclear localization in both these cell lines 
appeared more pronounced. This experiment given to us a reason to speculate 
about the different response to CDDP between these two cell lines; infact, it 
seems that the different localization of Fox03A protein in the cell during CDDP 
treatment alone could indicate that this transcription factor plays a role in the 
response to this chemotherapeutic. To link this nuclear accumulation with a 
functional role of Fox03A, we treated both cell lines with SB and CDDP alone or 
in combination for 48 hours and we made a quantitative real time PCR analysis 
of its targets genes, involved in cell death, such as PTEN and BIM , cell growth 
arrest, such as p21, and damage-activated gene, such as GADD45 (Figure 37}. As 
it is indicated in the graphs, in HCT116 cells these genes were upregulated when 
treated with CDDP alone and they were more upregulated when treated together 
with SB. Conversely, in HT29 cells the expression of these genes during CDDP 
treatment is similar to the DMSO-treated cells, while is upregulated when CDDP 
was used together with SB. The mRNA levels of these genes seemed to be in line 
with the localization of Fox03A in the nuclei (see Figure 35 and 36). Indeed, the 
upregulation of these genes during the co-treatment with CDDP and SB seemed
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Figure 37. Fox03A target genes are upregulated during co-treatment in both 
CRC cell lines. CRC cells were treated for 48 hours with DMSO, SB (10pM), 
CDDP (30pM) and CDDP plus SB. Real time PCR of putative Fox03A target 
genes was performed to correlate the nuclear localization of this transcription 
factor (see Figures 22 and 23) with its transcriptional activity. Worth of note is 
that HT29 cells did not upregulate these genes during CDDP treatment, while it 
happened when the two drugs were added together. Moreover, in HCT116 cells 
treated with CDDP alone are able to upregulate these genes and during the co­
treatment this upregulation is higher than the compounds alone. This different 
outcomes in CDDP treatment of the two CRC cell lines reflected the differences 
of the nuclear localization of Fox03A (see. Figures 22 and 23, CDDP panels), 
indicating a possible positive role in CDDP sensitiveness in CRC cell lines, beta- 
actin was used as calibrator of mRNA quantity. The relative mRNA levels are 
expressed as fold induction. Results are expressed as mean ±SEM (n=3). 
Comparison of mRNA levels of genes evaluated among each treatment was 
performed using a student’s t test followed by Mann-Witney U test 
(*/**=/7<0.05).
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to match with the strong accumulation of Fox03A in the nuclei during the co­
treatment in both cell lines. To confirm the role of Fox03A in the induction of 
apoptosis, we decided to silence Fox03A gene with siRNA technology in both 
cell lines for 36 hours. After this period we treated HCT116 cells with CDDP 
alone and HT29 cells with CDDP plus SB for 48 hours and we performed a blot 
analysis of p85 (Figure 38). The absence of Fox03A affected the cleavage of 
PARP-1 in both cell lines, suggesting that Fox03A could play a role in the 
activation of the apoptotic pathway.
Taken all these evidences, we may hypothesize that the inhibition of p38 alpha in 
CRC could be helpful in the treatment of this pathology with CDDP. Indeed, not 
only this inhibition improved the response to CDDP in a cell line sensitive 
(HCT116) but made a non responsive cell line (HT29) sensitive to this 
compound. These interesting results seemed to be driven by Fox03 A. Indeed, the 
different localization of this protein in the two CRC cell lines could explain the 
different outcomes in response to CDDP treatment. However, its nuclear 
localization could be associated with its dependent gene transcription and its 
absence affect the cleavage of PARP-1, suggesting that this transcription factor 
could play an important role in the activation of apoptotic response.
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Figure 38. Fox03A is necessary for apoptotic pathway. HCT116 cells and 
HT29 cells were silenced for Fox03A for 36 hours. After 36 hours HCT116 cells 
were treated with CDDP (30pM) for 48 hours while HT29 cells were treated with 
CDDP (3 0 jiM ) and SB (lOpM) for 48 hours. Immunoblot for Fox03A and p85 
proteins was performed. As shown in the picture, the silencing of Fox03A 
induced a decrease of p85 protein levels, indicating that the apoptosis triggered 
by CDDP in HCT116 cells and by the co-treatment in HT29 cells is driven by 
this transcription factor. This experiment enhanced the positive role of Fox03A 
in the sensitization of CRC cells to CDDP treatment. Actin was used for loading 
control. The pictures shown are representative of three replicates.
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Chapter R: DISCUSSION
Cancer is a major public health problem in the United States and in many other 
parts of the world. In the United States 25% of deaths are due to cancer (Siegel et 
al., 2012). Over the past 30 years, significant progress has been achieved in 
understanding the molecular basis of cancer. The accumulation of this basic 
knowledge has established that cancer is a variety of distinct diseases and that 
defective genes cause these diseases.
CRC, OvCa and PCa are very common neoplasia in western countries. Different 
approaches have been studied in these years to counteract the progression of 
these malignancies; therapies were initially based on the use of 
chemotherapeutics alone, then on the concomitant administration of traditional 
chemotherapeutics and biological molecules and lastly on the administration of 
antibodies targeting specific membrane receptors overexpressed in tumors.
All these strategies, however, revealed many weaknesses due to side effects on 
the patient's health (chemotherapeutics) or mutations in the downstream enzymes 
of therapy targets (antibodies), making the treatment of these types of cancer 
ineffective. Moreover, chemoresistance is the cause of negative response to 
treatment and even if the improvement of new strategies is a hopeful signal for 
the future, much has still to be done.
Deregulation of the pathways targeted by chemotherapy is the cause of the 
common treatment failure, making necessary the use of new therapeutic 
approaches.
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p38 alpha is a member of a group of four kinases that are activated by external 
stimuli, and are involved in different pathways such as myogenesis, 
inflammation, cancer, neurodegenerative disorders (Cuenda and Rousseau, 2007), 
as well as, in the regulation of autophagy (Webber and Tooze, 2010). Moreover, 
its inhibition in CRC cell lines induced cell cycle arrest, autophagy and then cell 
death, with autophagic features (Comes et al.,2007).
The aim of my PhD project was to investigate the possible causes of this 
autophagic activation in CRC cell lines during SB treatment. For this purpose we 
evaluated whether could exist variation of ATP levels, finding that they 
decreased during p38 alpha inhibition. The best established mechanism to 
produce ATP in tumors is glycolysis (Warburg, 1956), and for this reason we 
decided to analyze whether this pathway was affected by p38 alpha inhibition. A 
body of glycolytic genes was downregulated during SB treatment.
The decrease of glucose consumption for the production of ATP was confirmed 
also by the reduction of glucose uptake and lactate release in the medium of SB 
treated cells. Given the fact that all the glycolitic genes taken in consideration and 
downregulated by SB treatment are well known target genes of HIF-1 alpha 
transcription factor we decided to focus our attention on this transcription factor.. 
The analysis of protein levels and transcriptional activity of HIF-1 alpha during 
SB treatment confirmed that p38 alpha inhibition was able to negatively affected 
HIF-1 alpha stabilization and to induce downregulation of its target genes. While 
glycolytic genes and glycolysis were downregulated by SB treatment, other 
pathways seemed to be induced by p38 alpha inhibition, as suggested by the
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overexpression of several genes involved in cell cycle, autophagy, and cell death 
(Conies et al., 2007). An in silico analysis performed by our group, indicated 
Fox03A as another important transcription factor that could be involved in the 
pharmacological inhibition of p38 alpha.
p38 alpha inhibition in CRC cell lines induced the activation of this transcription 
factor with the consequent shift from a HIF-1 alpha to a Fox03A-dependent 
transcription pattern. Indeed, AMPK that is an upstream regulator of Fox03A 
was activated with SB treatment, whereas AKT, a negative regulator of this 
protein, was inhibited. Moreover, the SB dependent-induction of Foxo3 A target 
genes involved in autophagy and cell death was avoided by AMPK inhibition via 
Compound C, suggesting a link between this kinases and p38 alpha inhibition. 
Similar encouraging results were obtained also in OvCa cell lines, where HIF-1 
alpha plays an important role for tumor progression and it is a marker for 
prognosis (Osada et al., 2007). Indeed, in OvCa cells SB treatment reduced the 
mRNA levels of HIF-1 alpha targets genes, while Foxo3A pathway was 
upregulated leading to cell death with autophagic features (Matrone et al., 2010). 
We also decided to evaluate the effects of SB treatment in PCa cell lines, where 
HIF-1 alpha is a key player for survival. Worth of note, the inhibition of p38 
alpha in PCa cells exhibited two different; in DU 145 cells SB-treatment induced 
apoptosis while in PC3 cells growth arrest. The analysis of molecular differences 
between these cell lines revealed that AMPK is not phosphorylated during SB 
treatment in DU 145 cells, since this cell line is lacking for LKB1 tumor 
suppressor protein. In this condition, autophagy is not activated and the metabolic
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impairment created during p38 alpha inhibition induces apoptotic cell death in 
DU 145 cells. Conversely, in PC3 cells SB treatment induced growth arrest and 
the activation of autophagy, showing that p38 alpha plays a central role in PCa 
progression. The different effects on the two cell lines were confirmed using 
some human biopsies samples, which differed for LKB1 presence. In human 
biopsies that showed the absence of LKB1, SB treatment caused cell death, 
revealing how p38 alpha could be used as a marker for a targeted therapy, 
especially when the biopsy reveals the loss of LKB1.
Different papers underlined in these years the role of p38 alpha in 
chemoresistance in CRC cell lines. Paillas and colleagues (Paillas et al., 2011) 
and Yang and colleagues (Yang et al., 2011) showed that the inhibition of this 
kinase decreased chemoresistance of CPT-11 and 5-FU treatment in CRC, 
respectively, suggesting an important role of this kinase during chemotherapy. 
For this reason, we decided to focus our attention on the possibility that p38 alpha 
could play a role also in CDDP resistance in CRC cell lines. In our experimental 
settings, we focused on two CRC cell lines HT29, which is considered resistant to 
CDDP treatment, and HCT116, which is considered sensitive to this compound. 
The inhibition of p38 alpha together with CDDP administration induced a strong 
cell death in both cell lines. Co-treated cells underwent apoptotic cell death, as 
shown by caspases activation and the cleavage of PARP-1. De Mattos and 
colleagues (Fernandez de et al., 2008) demonstrated also that Fox03A played an 
important role in chemoresistance in CRC cell lines, and our previous papers 
indicated that the inhibition of p38 alpha induced the transcription activity of this
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protein (Chiacchiera et al., 2009; Matrone et al., 2010). Finally, we showed that 
during the co-treatment of CRC cell lines Fox03A translocated in to the nuclei 
and activated its dependent transcription. Moreover, its absence affected the 
activation of apoptotic pathway.
In this study, p38 alpha seems to be linked to HIF-1 alpha stability, whose 
absence produces a decrease of glycolytic genes transcription, preventing the 
production of ATP. This impairment of the energetic reservoir activated different 
pathway such as cell cycle arrest, autophagy and then cell death, driven by 
Fox03A transcription factor. Indeed, targeting cancer metabolism is one of the 
main goal of cancer research and an increasing number of researchers is focusing 
its attention on this topic. The identification of p38 alpha as one of the actors in 
this scenario could open to new strategies to fight these malignancies, especially 
when it is overactive. Moreover, the inhibition of this kinase seems to be 
fundamental to avoid resistance in CDDP treatment of CRC suggesting that this 
effect could be very helpful for future therapies especially for the chance to 
decrease the amount of chemotherapeutics used, overcoming all side effects for 
patient health. Worthy of note is that the effect of SB treatment on these cancer 
cell lines seemed to be linked to the possibility to activate Fox03A transcription 
factor. This is a very important point because this transcription factor is been 
linked to the activation of cell cycle arrest and autophagy and in the last years it 
is emerging its role as tumor suppressor. Moreover, the possibility to modify its 
regulator pathways by the use of a biological compound as SB, strongly makes 
Fox03A an instrument for the creation of new approaches in cancer therapy. The
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inhibition of p38 alpha represents a very hopeful instrument for treatment of 
cancer, and this promising result is validated through in vivo APC+/~ mouse 
model; indeed, SB treatment is able to cause a great reduction both in number and 
volume of intestinal tumors (Chiacchiera et al., 2009) without damaging the 
whole body homeostasis. Another interesting point, is that p38 alpha inhibition 
could be used to exacerbate the activation of autophagy. Indeed, when the 
activation of p38 alpha is restored by 48 hours, CRC cells are able to survive and 
to growth (Comes et al., 2007), indicating that autophagy could be used as a 
mechanism to survive in these cells. This is in agreement with the fact that CRC 
cells when treated with the inhibitor of autophagy 3-MA plus SB underwent 
apoptosis (Comes et al., 2007). This speculative conclusion could explain why 
PC3 cells dead when autophagy cannot be activated (DU 145 cells) and are able to 
growth when autophagy is activated by SB treatment (PC3 cells). However, to 
better evaluate the role of autophagy in PCa cells are necessary more 
experiments, such as use 3-MA with SB or the silencing of AMPK  gene. 
Autophagy plays a very crucial point in this scenario because, in some cases, 
mutations or epigenetic changes in the most important effectors of apoptotic 
pathway, such as p53, make ineffective the induction of the apoptotic cell death, 
undermining all efforts to trigger it. The strategy of autophagy activation to 
counteract cancer would give the possibility to overcome these obstacles and also 
would give the opportunity to ameliorate patient's health avoiding toxic 
compounds. Finally, the use of a biological compound in CRC such as SB 
together with a widely used chemotherapeutic could overcome many of the
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problems related to chemoresistance, making this kinase a putative target 
molecule for cancer therapy.
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ABBREVIATIONS
5-FU: (5-fluorouracil)
ACC: (Acetyl CoA Carboxylase)
AMPK: (AMP-activated Protein Kinase)
APC: (adenomatous polyposis coli)
AR: (androgen receptor)
ATF1: (activating transcription factor 1)
BAF60: (BRG1-associated factor 60)
BAK: (BCL2-antagonist/killer 1)
BAX: (BCL2-associated X protein)
BCL2: (B-cell CLL/lymphoma 2)
BCL-W: (BCL2-like 2)
BCL-XL: (BCL2-like 1)
BH: (BCL2 homology)
BID: (BH3 interacting domain death agonist)
BRCA: (breast cancer)
BRG1: (brahma-related gene 1)
BV: (bevacizumab)
CBP: (CREB binding protein)
CC: (Compound C)
CDDP: (cisplatin)
CDKI: (cyclin-dependent kinase inhibitors)
cDNA: (DNA complementary)
cFLIP: (cellular FLICE-like inhibitory protein)
CKI: (casein kinase 1)
CNS: (central nervous system)
CPT-11: (irinotecan)
CRC: (colorectal cancer)
CREB: (cAMP responsive element binding protein)
CTNNB1: (beta catenin)
DAPk: (death associated protein kinase)
DBD: (DNA-binding domain)
DDB2: (damaged-DNA-binding complex 2)
DFO: (desferrioxamine)
DMSO: (Dimethyl sulfoxide)
EGF: (epidermal growth factor)
EGFR: (epidermal growth factor receptor)
ERK: (extracellular signal-regulated kinase)
FAP: (familial adenomatous polyposis)
FGFR1: (fibroblast growth factor receptor 1)
FIGO: (international federation of gynecology and obstretics)
FIH: (factor inhibiting HIF)
FOLFOX: (oxaliplatin, 5-FU and leucovorin combination)
Fox: (Forkhead box)
GAPDH: (glyceraldehyde-3 -phosphate dehydrogenase)
GI: (gastrointestinal)
GLUT1: (Glucose transporter 1)
GSK3b: (glycogen synthase kinase 3 beta)
HIF-1 alpha: (hypoxia-inducible factor 1 alpha)
1R1
HK2: (hexokinase 2)
HNPCC: (hereditary nonpolyposis colorectal cancer)
HPP: (hyperplastic polyposis)
H-RAS: (Harvey rat sarcomas)
HSP: (heat shock protein)
HuR: (human antigen R)
IFL: (irinotecan, 5-FU and leucovorin combination)
IL: (interleukin)
JNK: (c-jun N-terminal kinase)
JPS: (juvenile polyposis syndrome)
K-RAS: (Kirsten rat sarcoma)
LDHa: (lactate dehydrogenase A)
LDL: (low density lipoprotein)
LKB1: (liver kinase B l)
LOH: (loss of heterozygosity)
LPS: (Lipopolysaccharide)
LRP: (low density lipoprotein receptor-related protein)
MAP: (MUTYH-associated polyposis)
MAP1LC3 or LC3: (microtubule-associated protein 1 light chain 3)
MAPK: (mitogen-activated protein kinases)
MCL1: (myeloid cell leukemia sequence 1)
MCP-1: (monocyte chemoattractant protein 1)
MEF: (mouse embryonic fibroblast)
MEF2: (myocyte enhancer factor)
MK2: (MAPK-activated protein kinase 2)
MKK: (MAPK kinase)
MKP: (MAPK phosphatase)
MLH: (mutL homolog)
MMP: (matrix metalloproteinase)
MMR: (DNA mismatch repair )
MSH: (mutS homolog)
MSI: (microsatellite instability)
MSK1: (Mitogen- and stress-activated protein kinase-1)
MUTYH: (mutY Homolog)
MYC: (myelocytomatosis viral oncogene homolog)
NHE-1: (microtubuleassociated protein tau, Na+/H+ exchanger 1)
NOXA: (Phorbol-12-myristate-13-acetate-induced protein 1)
N-RAS: (neuroblastoma RA S)
ODDD: (oxygen-dependent degradation domain)
OS: (overall survival)
OvCa: (ovarian cancer)
OXPHOS: (oxidative phosphorylation)
P.I.: (propidium iodide)
p38IP: (p38 alpha-interacting protein)
PAK: (p21 protein (Cdc42/Rac)-activated kinase 1)
PARP-1: (Poly (ADP-ribose) polymerase-1)
PBS: (phosphate-buffered saline)
PCa: (prostate cancer)
PCD: (programmed cell death)
PCR: (polymerase chain reaction)
1R3
PDH: (pyruvate dehydrogenase)
PDK1: (pyruvate dehydrogenase kinase 1)
PFS: (progression-free survival)
PHD: (prolyl hydroxylases domain)
PI3K: (phosphoinositol 3-kinase)
PIN: (prostatic intraepithelial neoplasia)
PJS: (Peutz-Jeghers syndrome)
PKM2: (pyruvate kinase isoform M2)
PMS: (postmeiotic segregation increased)
PP2C: (serine/threonine protein phosphotase type 2C)
PRAK: (p38 regulated/activated kinase)
PTEN: (phosphatase and tensin homolog 10)
PUMA: (BCL2 binding component 3)
pVHL: (von Hippel-Lindau protein)
RAF: (v-raf-1 murine leukemia viral oncogene homolog)
RAS: (rat sarcomas)
Rb: (retinoblastoma protein9)
ROS: (reactive oxygen species)
RR: (response rate)
SAPK: (stress-activated protein kinases)
SB: (SB202190)
SFRP: (secreted frizzled-related protein)
SMAC: (second mitochondria-derived activator of caspase)
SRF: (serum response factor)
STK11: (serine-threonine kinase 11)
1R4
SV40: (simian virus 40)
SWI/SNF: (switch/sucrose nonfermentable)
TAB: (TAK binding protein)
TAK: (TGF-beta-activated protein kinase)
TCF: (T-cell factor)
TGFbetallR: (transforming growth factor, beta receptor II)
TNF: (tumor necrosis factor)
TSC: (tuberous sclerosis)
TTP: (time to progression)
USF1: (upstream stimulatory factor 1)
VEGF: (vascular endothelial growth factor)
vFLIP: (viral FLICE-like inhibitory protein)
WIF: (WNT inhibitor factor)
WNT: (wingless-type MMTV integration site family)
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